U.S. patent application number 10/756623 was filed with the patent office on 2004-07-29 for methods of using dihydropteridinones.
This patent application is currently assigned to Boehringer Ingelheim Pharma Gmbh & Co. KG. Invention is credited to Bauer, Eckhart, Breitfelder, Steffen, Eickmeier, Christian, Grauert, Matthias, Hoffmann, Matthias, Lehmann-Lintz, Thorsten, Phol, Gerald, Quant, Jens, Redemann, Norbert, Schnapp, Gisela, Steegmaier, Martin.
Application Number | 20040147524 10/756623 |
Document ID | / |
Family ID | 31498915 |
Filed Date | 2004-07-29 |
United States Patent
Application |
20040147524 |
Kind Code |
A1 |
Bauer, Eckhart ; et
al. |
July 29, 2004 |
Methods of using dihydropteridinones
Abstract
Disclosed are dihydropteridinones of the formula (I): 1 wherein
the groups X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and
R.sup.7 have the meanings given in the claims and specification,
the isomers thereof, processes and intermediates for preparing
these dihydropteridinones as well as the use thereof as
pharmaceutical compositions.
Inventors: |
Bauer, Eckhart; (Biberach,
DE) ; Breitfelder, Steffen; (Assmannshardt, DE)
; Eickmeier, Christian; (Mittelbiberach, DE) ;
Grauert, Matthias; (Biberach, DE) ; Hoffmann,
Matthias; (Mittelbiberach, DE) ; Lehmann-Lintz,
Thorsten; (Ochsenhausen, DE) ; Phol, Gerald;
(Biberach, DE) ; Quant, Jens; (Guntramsdorf,
AU) ; Redemann, Norbert; (Biberach, DE) ;
Schnapp, Gisela; (Biberach-Rindenmoos, DE) ;
Steegmaier, Martin; (Wien, AT) |
Correspondence
Address: |
BOEHRINGER INGELHEIM CORPORATION
900 RIDGEBURY ROAD
P. O. BOX 368
RIDGEFIELD
CT
06877
US
|
Assignee: |
Boehringer Ingelheim Pharma Gmbh
& Co. KG
Binger Strasse 173
Ingelheim
DE
55216
|
Family ID: |
31498915 |
Appl. No.: |
10/756623 |
Filed: |
January 13, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10756623 |
Jan 13, 2004 |
|
|
|
10226710 |
Aug 23, 2002 |
|
|
|
60332681 |
Nov 14, 2001 |
|
|
|
Current U.S.
Class: |
514/251 |
Current CPC
Class: |
C07D 487/04 20130101;
C07D 475/00 20130101 |
Class at
Publication: |
514/251 |
International
Class: |
A61K 031/525 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 4, 2001 |
DE |
101 43 272.0 |
Claims
1. A method of treating a disease or condition chosen from cancer,
infections, inflammatory and autoimmune diseases said method
comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of the formula (I),
1368wherein R.sup.1 denotes a group selected from among hydrogen,
NH.sub.2, XH, halogen and a C.sub.1-C.sub.3-alkyl group optionally
substituted by one or more halogen atoms, R.sup.2 denotes a group
selected from among hydrogen, CHO, XH, --X--C.sub.1-C.sub.2-alkyl
and an optionally substituted C.sub.1-C.sub.3-alkyl group, R.sup.3,
R.sup.4 are identical or different and denote a group selected from
among optionally substituted C.sub.1-C.sub.10-alkyl,
C.sub.2-C.sub.10-alkenyl, C.sub.2-C.sub.10-alkyny- l, aryl,
heteroaryl, C.sub.3-C.sub.8-cycloalkyl, C.sub.3-C.sub.8-heterocyc-
loalkyl, --X-aryl, --X-heteroaryl, --X-cycloalkyl,
--X-heterocycloalkyl, --NR.sup.8-aryl, --NR.sup.8-heteroaryl,
--NR.sup.8-cycloalkyl,- and --NR.sup.8-heterocycloalkyl, or a group
selected from among hydrogen, halogen, COXR.sup.8,
CON(R.sup.8).sub.2, COR.sup.8 and XR.sup.8, or R.sup.3 and R.sup.4
together denote a 2- to 5-membered alkyl bridge which may contain 1
to 2 heteroatoms, R.sup.5 denotes hydrogen or a group selected from
among optionally substituted C.sub.1-C.sub.10-alkyl,
C.sub.2-C.sub.10-alkenyl, C.sub.2-C.sub.10-alkynyl, aryl,
heteroaryl and --C.sub.3-C.sub.6-cycloalkyl , or R.sup.3 and
R.sup.5 or R.sup.4 and R.sup.5 together denote a saturated or
unsaturated C.sub.3-C.sub.4-alkyl bridge which may contain 1 to 2
heteroatoms, R.sup.6 denotes optionally substituted aryl or
heteroaryl, R.sup.7 denotes hydrogen or
--CO--X--C.sub.1-C.sub.4-alkyl, and X in each case independently of
one another denotes O or S, and R.sup.8 in each case independently
of one another denotes hydrogen or a group selected from among
optionally substituted C.sub.1-C.sub.4-alkyl,
C.sub.2-C.sub.4-alkenyl, C.sub.2-C.sub.4-alkynyl and phenyl, or the
tautomers, the racemates, the enantiomers, the diastereomers and
the mixtures thereof, and optionally the pharmacologically
acceptable acid addition salts thereof.
2. A method of treating a disease or condition chosen from HIV,
Kaposi's sarcoma, colitis, arthritis, Alzheimer's disease,
glomerulonephritis, conditions related to wound healing, bacterial,
fungal and/or parasitic infections, leukaemias, lymphoma, solid
tumours, psoriasis, bone diseases and cardiovascular disease
comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of formula (I)
1369wherein R.sup.1 denotes a group selected from among hydrogen,
NH.sub.2, XH, halogen and a C.sub.1-C.sub.3-alkyl group optionally
substituted by one or more halogen atoms, R.sup.2 denotes a group
selected from among hydrogen, CHO, XH, --X--C.sub.1-C.sub.2-alkyl
and an optionally substituted C.sub.1-C.sub.3-alkyl group, R.sup.3,
R.sup.4 are identical or different and denote a group selected from
among optionally substituted C.sub.1-C.sub.10-alkyl,
C.sub.2-C.sub.10-alkenyl, C.sub.2-C.sub.10-alkynyl, aryl,
heteroaryl, C.sub.3-C.sub.8-cycloalkyl,
C.sub.3-C.sub.8-heterocycloalkyl, --X-aryl, --X-heteroaryl,
--X-cycloalkyl, --X-heterocycloalkyl, --NR.sup.8-aryl,
--NR.sup.8-heteroaryl, --NR.sup.8-cycloalkyl,- and
--NR.sup.8-heterocycloalkyl, or a group selected from among
hydrogen, halogen, COXR.sup.8, CON(R.sup.8).sub.2, COR.sup.8 and
XR.sup.8, or R.sup.3 and R.sup.4 together denote a 2- to 5-membered
alkyl bridge which may contain 1 to 2 heteroatoms, R.sup.5 denotes
hydrogen or a group selected from among optionally substituted
C.sub.1-C.sub.10-alkyl, C.sub.2-C.sub.10-alkenyl,
C.sub.2-C.sub.10-alkynyl, aryl, heteroaryl and
--C.sub.3-C.sub.6-cycloalkyl , or R.sup.3 and R.sup.5 or R.sup.4
and R.sup.5 together denote a saturated or unsaturated
C.sub.3-C.sub.4-alkyl bridge which may contain 1 to 2 heteroatoms,
R.sup.6 denotes optionally substituted aryl or heteroaryl, R.sup.7
denotes hydrogen or --CO--X--C.sub.1-C.sub.4-alkyl, and X in each
case independently of one another denotes O or S, and R.sup.8 in
each case independently of one another denotes hydrogen or a group
selected from among optionally substituted C.sub.1-C.sub.4-alkyl,
C.sub.2-C.sub.4-alkenyl, C.sub.2-C.sub.4-alkynyl and phenyl, or the
tautomers, the racemates, the enantiomers, the diastereomers and
the mixtures thereof, and optionally the pharmacologically
acceptable acid addition salts thereof.
3. The methods according to claims 1 or 2 wherein for the formula
(I) R.sup.1 denotes hydrogen, R.sup.2 denotes a group selected from
among a CHO, OH, and CH.sub.3 group, R.sup.3, R.sup.4 are identical
or different and denote a group selected from among hydrogen,
optionally substituted C.sub.1-C.sub.6-alkyl,
C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl,
C.sub.3-C.sub.7-cycloalkyl, or R.sup.3 and R.sup.4 together denote
a C.sub.2-C.sub.5-alkyl bridge, R.sup.5 denotes a group selected
from among optionally substituted C.sub.1-C.sub.10-alkyl,
C.sub.2-C.sub.10-alkenyl, C.sub.2-C.sub.10-alkynyl,
C.sub.3-C.sub.6-cycloalkyl and C.sub.3-C.sub.6-cycloalkenyl, or
R.sup.3 and R.sup.5 or R.sup.4 and R.sup.5 together denote a
saturated or unsaturated C.sub.3-C.sub.4-alkyl bridge which may
contain 1 to 2 heteroatoms, and R.sup.7 denotes hydrogen.
4. The methods according to claim 3, wherein for the formula (I)
R.sup.6 denotes a group of general formula 1370wherein n denotes 1,
2, 3 or 4, R.sup.9 denotes a group selected from among optionally
substituted C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl,
C.sub.2-C.sub.6-alkynyl, --CONH--C.sub.1-C.sub.10-alkylene,
--O-aryl, --O-heteroaryl, --O-cycloalkyl, --O-heterocycloalkyl,
aryl, heteroaryl, cycloalkyl and heterocycloalkyl or a group
selected from among --O--C.sub.1-C.sub.6-alky- l-Q.sup.1,
--CONR.sup.8--C.sub.1-C.sub.10-alkyl-Q.sup.1,
--CONR.sup.8--C.sub.2-C.sub.10-alkenyl-Q.sup.1,
--CONR.sup.8--Q.sup.2, halogen, OH, --SO.sub.2R.sup.8,
--SO.sub.2N(R.sup.8).sub.2, --COR.sup.8, --COOR.sup.8,
--N(R.sup.8).sub.2, --NHCOR.sup.8, CONR.sup.8OC.sub.1-C.sub- .10
alkylQ.sup.1 and CONR.sup.8OQ.sup.2, Q.sup.1 denotes hydrogen,
--NHCOR.sup.8, or a group selected from among an optionally
substituted --NH-aryl, --NH-heteroaryl, aryl, heteroaryl,
C.sub.3-C.sub.8-cycloalkyl- and heterocycloalkyl group, Q.sup.2
denotes hydrogen or a group selected from among an optionally
substituted aryl, heteroaryl, C.sub.3-C.sub.8-heterocycloalkyl,
C.sub.3-C.sub.8-cycloalkyl- and
C.sub.1-C.sub.4-alkyl-C.sub.3-C.sub.8-cycloalkyl group, R.sup.10 is
identical or different and denotes a group selected from among
optionally substituted C.sub.1-C.sub.6-alkyl ,
C.sub.2-C.sub.6-alkenyl and C.sub.2-C.sub.6-alkynyl,
--O--C.sub.1-C.sub.6-alkyl, --O--C.sub.2-C.sub.6-alkenyl,
--O--C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-heterocycloalkyl and
C.sub.3-C.sub.6-cycloalkyl, or a group selected from among
hydrogen, --CONH.sub.2, --COOR.sup.8, --OCON(R.sup.8).sub.2,
--N(R.sup.8).sub.2, --NHCOR.sup.8, --NHCON(R.sup.8).sub.2,
--NO.sub.2 and halogen, or adjacent groups R.sup.9 and R.sup.10
together denote a bridge of the formula 1371Y denotes O, S or
NR.sup.11, m denotes 0, 1 or 2 R.sup.11 denotes hydrogen or
C.sub.1-C.sub.2-alkyl, and R.sup.12 denotes hydrogen or a group
selected from among optionally substituted phenyl, pyridyl,
pyrazinyl, pyrimidinyl, pyridazinyl,
--C.sub.1-C.sub.3-alkyl-phenyl, --C.sub.1-C.sub.3-alkyl-pyridyl,
--C.sub.1-C.sub.3-alkyl-pyrazinyl,
--C.sub.1-C.sub.3-alkyl-pyrimidinyl and
--C.sub.1-C.sub.3-alkyl-pyridazin- yl, and R.sup.13 denotes
C.sub.1-C.sub.6-alkyl.
5. The methods according to claim 4, wherein for the formula (I)
R.sup.1 denotes hydrogen, R.sup.2 denotes CH.sub.3, and R.sup.7
denotes hydrogen.
6. A method of treating a disease or condition chosen from cancer,
infections, inflammatory and autoimmune diseases said method
comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of the formula (II),
1372wherein R.sup.1-R.sup.5 and X have the meanings given in claim
1.
7. A method of treating a disease or condition chosen from HIV,
Kaposi's sarcoma, colitis, arthritis, Alzheimer's disease,
glomerulonephritis, conditions related to wound healing, bacterial,
fungal and/or parasitic infections, leukaemias, lymphoma, solid
tumours, psoriasis, bone diseases and cardiovascular disease
comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of the formula (II),
1373wherein R.sup.1-R.sup.5 and X have the meanings given in claim
1.
Description
APPLICATION DATA
[0001] This application is a continuation of U.S. application Ser.
No. 10/226,710 filed Aug. 23, 2002 which claims benefit to DE 101
43 272.0 filed Sep. 4, 2001 and U.S. provisional application No.
60/332681 filed Nov. 14, 2001.
FIELD OF THE INVENTION
[0002] The present invention relates to new dihydropteridinones of
general formula (I) 2
[0003] wherein the groups X, R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 have the meanings given in the claims
and specification, the isomers thereof, processes for preparing
these dihydropteridinones and the use thereof as pharmaceutical
compositions.
BACKGROUND TO THE INVENTION
[0004] Pteridinone derivatives are known from the prior art as
active substances with an antiproliferative activity. WO 01/019825
describes the use of pteridinone derivatives for the treatment of
neoplastic and viral diseases. The resistance of many types of
tumours calls for the development of new pharmaceutical
compositions for combating tumours.
[0005] The aim of the present invention is to prepare new compounds
with an antiinflammatory and antiproliferative activity.
DETAILED DESCRIPTION OF THE INVENTION
[0006] Surprisingly it has been found that compounds of general
formula (I) wherein the groups X and R.sup.1 to R.sup.7 have the
meanings given hereinafter act as inhibitors of specific cell cycle
kinases. Thus, the compounds according to the invention may be used
for example to treat diseases connected with the activity of
specific cell cycle kinases and characterised by excessive or
abnormal cell proliferation.
[0007] The present invention therefore relates to compounds of
general formula (I) 3
[0008] wherein
[0009] R.sup.1 denotes a group selected from among hydrogen,
NH.sub.2, XH, halogen and a C.sub.1-C.sub.3-alkyl group optionally
substituted by one or more halogen atoms,
[0010] R.sup.2 denotes a group selected from among hydrogen, CHO,
XH, --X--C.sub.1-C.sub.2-alkyl and an optionally substituted
C.sub.1-C.sub.3-alkyl group,
[0011] R.sup.3, R.sup.4 which may be identical or different denote
a group selected from among optionally substituted
C.sub.1-C.sub.10-alkyl, C.sub.2-C.sub.10-alkenyl,
C.sub.2-C.sub.10-alkynyl, aryl, heteroaryl,
C.sub.3-C.sub.8-cycloalkyl, C.sub.3-C.sub.8-heterocycloalkyl,
--X-aryl, --X-heteroaryl, --X-cycloalkyl, --X-heterocycloalkyl,
--NR.sup.8-aryl, --NR.sup.8-heteroaryl, --NR.sup.8-cycloalkyl and
--NR.sup.8-heterocycloal- kyl, or a group selected from among
hydrogen, halogen, COXR.sup.8, CON(R.sup.8).sub.2, COR.sup.8 and
XR.sup.8, or
[0012] R.sup.3 and R.sup.4 together denote a 2- to 5-membered alkyl
bridge which may contain 1 to 2 heteroatoms,
[0013] R.sup.5 denotes hydrogen or a group selected from among
optionally substituted C.sub.1-C.sub.10-alkyl,
C.sub.2-C.sub.10-alkenyl, C.sub.2-C.sub.10-alkynyl, aryl,
heteroaryl and --C.sub.3-C.sub.6-cycloalk- yl, or
[0014] R.sup.3 and R.sup.5 or R.sup.4 and R.sup.5 together denote a
saturated or unsaturated C.sub.3-C.sub.4-alkyl bridge which may
contain 1 to 2 heteroatoms,
[0015] R.sup.6 denotes optionally substituted aryl or
heteroaryl,
[0016] R.sup.7 denotes hydrogen or --CO--X--C.sub.1-C.sub.4-alkyl,
and
[0017] X in each case independently of one another denotes O or
S,
[0018] R.sup.8 in each case independently of one another denotes
hydrogen or a group selected from among optionally substituted
C.sub.1-C.sub.4-alkyl, C.sub.2-C.sub.4-alkenyl,
C.sub.2-C.sub.4-alkynyl and phenyl,
[0019] optionally in the form of the tautomers, the racemates, the
enantiomers, the diastereomers and the mixtures thereof, and
optionally the pharmacologically acceptable acid addition salts
thereof.
[0020] Preferred compounds of formula (I) are those wherein
[0021] X and R.sup.6 have the meaning indicated, and
[0022] R.sup.1 denotes hydrogen,
[0023] R.sup.2 denotes a group selected from among a CHO, OH, and
CH.sub.3 group,
[0024] R.sup.3, R.sup.4 which may be identical or different denote
a group selected from among hydrogen, optionally substituted
C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl,
C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.7-cycloalkyl, or
[0025] R.sup.3 and R.sup.4 together denote a C.sub.2-C.sub.5-alkyl
bridge,
[0026] R.sup.5 denotes a group selected from among optionally
substituted C.sub.1-C.sub.10-alkyl, C.sub.2-C.sub.10-alkenyl,
C.sub.2-C.sub.10-alkyny- l, C.sub.3-C.sub.6-cycloalkyl and
C.sub.3-C.sub.6-cycloalkenyl, or
[0027] R.sup.3 and R.sup.5 or R.sup.4 and R.sup.5 together denote a
saturated or unsaturated C.sub.3-C.sub.4-alkyl bridge which may
contain 1 to 2 heteroatoms, and
[0028] R.sup.7 denotes hydrogen,
[0029] optionally in the form of the tautomers, the racemates, the
enantiomers, the diastereomers and the mixtures thereof, and
optionally the pharmacologically acceptable acid addition salts
thereof.
[0030] Particularly preferred compounds of formula (I) are those
wherein
[0031] R.sup.1-R.sup.5, R.sup.7, R.sup.8 and X have the meaning
indicated, and
[0032] R.sup.6 denotes a group of general formula 4
[0033] wherein
[0034] n denotes 1, 2, 3 or 4,
[0035] R.sup.9 denotes a group selected from among optionally
substituted C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl,
C.sub.2-C.sub.6-alkynyl, --CONH--C.sub.1-C.sub.10-alkylene,
--O-aryl, --O-heteroaryl, --O-cycloalkyl, --O-heterocycloalkyl,
aryl, heteroaryl, cycloalkyl and heterocycloalkyl or a group
selected from among --O--C.sub.1-C.sub.6-alky- l-Q.sup.1,
--CONR.sup.8--C.sub.1-C.sub.10-alkyl-Q.sup.1,
--CONR.sup.8--C.sub.2-C.sub.10-alkenyl-Q.sup.1,
--CONR.sup.8--Q.sup.2, halogen, OH, --SO.sub.2R.sup.8,
--SO.sub.2N(R.sup.8).sub.2, --COR.sup.8,--COOR.sup.8,
--N(R.sup.8).sub.2, --NHCOR.sup.8, CONR.sup.8OC.sub.1-C.sub.10
alkylQ.sup.1 and CONR.sup.8OQ.sup.2,
[0036] Q.sup.1 denotes hydrogen, --NHCOR.sup.8, or a group selected
from among an optionally substituted --NH-aryl, --NH-heteroaryl,
aryl, heteroaryl, C.sub.3-C.sub.8-cycloalkyl- and heterocycloalkyl
group,
[0037] Q.sup.2 denotes hydrogen or a group selected from among an
optionally substituted aryl, heteroaryl,
C.sub.3-C.sub.8-heterocycloalkyl- , C.sub.3-C.sub.8-cycloalkyl- and
C.sub.1-C.sub.4-alkyl-C.sub.3-C.sub.8-cy- cloalkyl group,
[0038] R.sup.10 which may be identical or different denotes a group
selected from among optionally substituted C.sub.1-C.sub.6-alkyl ,
C.sub.2-C.sub.6-alkenyl and C.sub.2-C.sub.6-alkynyl,
--O--C.sub.1-C.sub.6-alkyl, --O--C.sub.2-C.sub.6-alkenyl,
--O--C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-heterocycloalkyl and
C.sub.3-C.sub.6-cycloalkyl, or a group selected from among
hydrogen, --CONH.sub.2, --COOR.sup.8, --OCON(R.sup.8).sub.2,
--N(R.sup.8).sub.2, --NHCOR.sup.8, --NHCON(R.sup.8).sub.2,
--NO.sub.2 and halogen, or
[0039] adjacent groups R.sup.9 and R.sup.10 together denote a
bridge of general formula 5
[0040] Y denotes O, S or NR.sup.11,
[0041] m denotes 0, 1 or 2
[0042] R.sup.11 denotes hydrogen or C.sub.1-C.sub.2-alkyl, and
[0043] R.sup.12 denotes hydrogen or a group selected from among
optionally substituted phenyl, pyridyl, pyrazinyl, pyrimidinyl,
pyridazinyl, --C.sub.1-C.sub.3-alkyl-phenyl,
--C.sub.1-C.sub.3-alkyl-pyridyl, --C.sub.1-C.sub.3-alkyl-pyrazinyl,
--C.sub.1-C.sub.3-alkyl-pyrimidinyl and
--C.sub.1-C.sub.3-alkyl-pyridazinyl, p1 R.sup.13 denotes
C.sub.1-C.sub.6-alkyl,
[0044] optionally in the form of the tautomers, the racemates, the
enantiomers, the diastereomers and the mixtures thereof, and
optionally the pharmacologically acceptable acid addition salts
thereof.
[0045] Particularly preferred are compounds of formula (I)
wherein
[0046] R.sup.3--R.sup.6, R.sup.8 and X have the meaning indicated,
and
[0047] R.sup.1 denotes hydrogen,
[0048] R.sup.2 denotes CH.sub.3, and
[0049] R.sup.7 denotes hydrogen,
[0050] optionally in the form of the tautomers, the racemates, the
enantiomers, the diastereomers and the mixtures thereof, and
optionally the pharmacologically acceptable acid addition salts
thereof.
[0051] The invention further relates to compounds of formula (I),
wherein X and R.sup.1-R.sup.7 have the meanings indicated, for use
as pharmaceutical compositions.
[0052] Of particular importance according to the invention are
compounds of formula (I), wherein X and R.sup.1-R.sup.7 have the
meaning indicated, for use as pharmaceutical compositions with an
antiproliferative activity.
[0053] The invention also relates to the use of a compound of
formula (I), wherein X and R.sup.1-R.sup.7 have the meaning
indicated, for preparing a pharmaceutical composition for the
treatment and/or prevention of cancer, infections, inflammatory and
autoimmune diseases.
[0054] The invention also relates to a method of treating and/or
preventing cancer, infections, inflammatory and autoimmune
diseases, characterised in that a patient is given an effective
amount of a compound of formula (I), wherein X and R.sup.1-R.sup.7
have the meanings indicated.
[0055] The invention also relates to pharmaceutical preparations,
containing as active substance one or more compounds of general
formula (I), wherein X and R.sup.1-R.sup.7 have the meanings
indicated, or the physiologically acceptable salts thereof,
optionally combined with conventional excipients and/or
carriers.
[0056] The invention also relates to a process for preparing a
compound of general formula (I), 6
[0057] wherein
[0058] R.sup.1-R.sup.7 and X are as hereinbefore defined,
characterised in that a compound of general formula (II) 7
[0059] wherein
[0060] R.sup.1-R.sup.5 and X are as hereinbefore defined and L is a
leaving group, is reacted with an optionally substituted compound
of general formula (III) 8
[0061] wherein
[0062] R.sup.6 and R.sup.7 are as hereinbefore defined.
[0063] The invention also relates to a compound of formula (II),
9
[0064] wherein
[0065] R.sup.1-R.sup.5 and X are as hereinbefore defined. Compounds
of formula (II) are important intermediate products for preparing
the compounds of formula (I) according to the invention.
[0066] The invention also relates to a process for preparing a
compound of general formula (I), 10
[0067] wherein
[0068] R.sup.6 denotes a group of general formula, 11
[0069] R.sup.9 denotes an optionally substituted group
--CONH--C.sub.1-C.sub.10-alkylene or a group selected from among
--CONR.sup.8--C.sub.1-C.sub.10-alkyl-Q.sup.1,
--CONR.sup.8--C.sub.2-C.sub- .10-alkenyl-Q.sup.1,
--CONR.sup.8--Q.sup.2 and --COOR.sup.8, and
[0070] R.sup.1-R.sup.5, R.sup.7, R.sup.10, n and X are as
hereinbefore defined, characterised in that a compound of general
formula (IA) 12
[0071] wherein
[0072] R.sup.1 to R.sup.5, R.sup.7 and R.sup.10 are as hereinbefore
defined, and
[0073] L denotes a leaving group,
[0074] is reacted with a primary or secondary amine to form the
corresponding amide or is reacted with an alcohol to form the
corresponding ester.
[0075] The term alkyl groups, including alkyl groups which are a
part of other groups, denotes branched and unbranched alkyl groups
with 1 to 10 carbon atoms, preferably 1-6, most preferably 1-4
carbon atoms, such as, for example: methyl, ethyl, propyl, butyl,
pentyl, hexyl, heptyl, octyl, nonyl and decyl. Unless otherwise
stated, the abovementioned terms propyl, butyl, pentyl, hexyl,
heptyl, octyl, nonyl and decyl include all the possible isomeric
forms. For example, the term propyl includes the two isomeric
groups n-propyl and iso-propyl, the term butyl includes n-butyl,
iso-butyl, sec. butyl and tert.-butyl, the term pentyl includes
iso-pentyl, neopentyl, etc.
[0076] In the abovementioned alkyl groups one or more hydrogen
atoms may optionally be replaced by other groups. For example these
alkyl groups may be substituted by the halogen atoms fluorine,
chlorine, bromine or iodine. The substituents fluorine and chlorine
are preferred. The substituent chlorine is particularly preferred.
All the hydrogen atoms of the alkyl group may optionally also be
replaced.
[0077] Similarly, in the abovementioned alkyl groups, unless
otherwise stated, one or more hydrogen atoms may optionally be
replaced for example by an optionally substituted group selected
from among CN, OCOCH.sub.3, aryl, preferably phenyl, heteroaryl,
preferably thienyl, thiazolyl, imidazolyl, pyridyl, pyrimidyl or
pyrazinyl, saturated or unsaturated heterocycloalkyl, preferably
pyrazolyl, pyrrolidinyl, piperidinyl, piperazinyl or
tetrahydro-oxazinyl, an amine group, preferably methylamine,
benzylamine, phenylamine or heteroarylamine, saturated or
unsaturated bicyclic ring systems, preferably benzimidazolyl and
cycloalkyl, preferably cyclohexyl or cyclopropyl.
[0078] The term alkyl bridge, unless otherwise stated, denotes
branched and unbranched alkyl groups with 2 to 5 carbon atoms, for
example propylene, isopropylene, n-butylene, iso-butyl, sec. butyl
and tert.-butyl etc. bridges. Propylene and butylene bridges are
particularly preferred. In the alkyl bridges mentioned 1 to 2
C-atoms may optionally be replaced by one or more heteroatoms
selected from among oxygen, nitrogen or sulphur.
[0079] The term alkenyl groups (including those which are a part of
other groups) denotes branched and unbranched alkylene groups with
2 to 10 carbon atoms, preferably 2-6 carbon atoms, most preferably
2-3 carbon atoms, provided that they have at least one double bond.
Examples include: ethenyl, propenyl, butenyl, pentenyl etc. Unless
otherwise stated, the abovementioned terms propenyl, butenyl, etc
also include all the possible isomeric forms. For example, the term
butylene includes n-butenyl, 1-methylpropenyl, 2-methylpropenyl,
1.1-dimethylethenyl, 1.2-dimethylethenyl etc.
[0080] In the abovementioned alkenyl groups, unless otherwise
stated, one or more hydrogen atoms may optionally be replaced by
other groups. For example, these alkyl groups may be substituted by
the halogen atoms fluorine, chlorine, bromine or iodine. The
substituents fluorine and chlorine are preferred. The substituent
chlorine is particularly preferred. All the hydrogen atoms of the
alkenyl group may optionally also be replaced.
[0081] The term alkynyl groups (including those which are a part of
other groups) denotes branched and unbranched alkynyl groups with 2
to 10 carbon atoms, provided that they have at least one triple
bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl
etc., preferably ethynyl or propynyl.
[0082] In the abovementioned alkynyl groups, unless otherwise
stated, one or more hydrogen atoms may optionally be replaced by
other groups. For example, these alkyl groups may be substituted by
the halogen atoms fluorine, chlorine, bromine or iodine. The
substituents fluorine and chlorine are preferred. The substituent
chlorine is particularly preferred. All the hydrogen atoms of the
alkynyl group may optionally also be replaced.
[0083] The term aryl denotes an aromatic ring system with 6 to 14
carbon atoms, preferably 6 or 10 carbon atoms, preferably phenyl,
which, unless otherwise stated, may carry one or more of the
following substituents, for example: OH, NO.sub.2, CN,
--OCHF.sub.2, --OCF.sub.3, --NH.sub.2, halogen, for example
fluorine, chlorine, bromine or iodine, preferably fluorine or
chlorine, C.sub.1-C.sub.10-alkyl, preferably C.sub.1-C.sub.5-alkyl,
preferably C.sub.1-C.sub.3-alkyl, most preferably methyl or ethyl,
--O--C.sub.1-C.sub.3-alkyl, preferably --O-methyl or --O-ethyl,
--N-methyl-tetrahydro-oxazinyl, --COOH,
--COO--C.sub.1-C.sub.4-alkyl, preferably --COOCH.sub.2CH.sub.3,
--COO--C(CH.sub.3).sub.3 or --COOCH.sub.3, --CONH.sub.2,
--CONH--C.sub.1-C.sub.10-alkyl, while this alkyl may optionally be
further substituted, optionally substituted
--CONH--C.sub.3-C.sub.6-cyclo- alkyl, preferably optionally
substituted --CONH-cyclopentyl, optionally substituted
--CONH-heterocycloalkyl, preferably piperidinyl, pyrrolidinyl or
piperazinyl, optionally substituted --CONH-heteroaryl, preferably
optionally substituted --CONH-pyridyl, optionally substituted
--CONH-aryl, preferably optionally substituted --CONH-phenyl,
--CONMeC.sub.1-C.sub.3-alkyl, while this alkyl may optionally be
further substituted, preferably --CONMeCH.sub.2-pyridyl,
benzimidazole or a group of formula 13
[0084] Examples of 5-10-membered mono- or bicyclic heteroaryl rings
wherein up to three C-atoms may be replaced by one or more
heteroatoms selected from among oxygen, nitrogen or sulphur include
furan, thiophene, pyrrole, pyrazole, imidazole, triazole,
tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine,
oxazole, isoxazole, thiazole, thiadiazole and oxadiazole, while
each of the abovementioned heterocycles may optionally also be
annellated onto a benzene ring, preferably benzimidazole, and
unless otherwise stated these heterocycles may for example carry
one or more of the following substituents: OH, NO.sub.2, CN,
--OCHF.sub.2, --OCF.sub.3, --NH.sub.2, halogen, preferably fluorine
or chlorine, C.sub.1-C.sub.10-alkyl, preferably
C.sub.1-C.sub.5-alkyl, preferably C.sub.1-C.sub.3-alkyl, most
preferably methyl or ethyl, --O--C.sub.1-C.sub.3-alkyl, preferably
--O-methyl or --O-ethyl, -methyl-N-tetrahydro-oxazinyl, --COOH,
--COO--C.sub.1-C.sub.4-alkyl, preferably --COO--C(CH.sub.3).sub.3
or --COOCH.sub.3, --CONH.sub.2, optionally substituted phenyl,
optionally substituted heteroaryl, preferably optionally
substituted pyridyl or pyrazinyl, --CONH--C.sub.1-C.sub.10-alkyl,
while this alkyl may itself optionally be substituted, optionally
substituted --CONH--C.sub.3-C.sub.6-cycloalkyl, preferably
optionally substituted --CONH-cyclopentyl, optionally substituted
--CONH-heteroaryl, preferably optionally substituted
--CONH-pyridyl, optionally substituted --CONH-aryl, preferably
optionally substituted --CONH-phenyl, --CONMeC.sub.1-C.sub.3-alkyl,
while this alkyl may itself optionally be substituted, preferably
--CONMeCH.sub.2-pyridyl, benzimidazole or a group of formula 14
[0085] The term cycloalkyl groups denotes, for example, saturated
or unsaturated cycloalkyl groups with 3-8 carbon atoms, for example
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl or cyclooctyl, preferably cyclopropyl,
cyclopentyl or cyclohexyl, while each of the abovementioned
cycloalkyl groups may optionally also carry one or more
substituents, preferably .dbd.O, or may be annellated to a benzene
ring.
[0086] ".dbd.O" denotes an oxygen atom linked via a double
bond.
[0087] The term heterocycloalkyl groups, unless otherwise described
in the definitions, may denote 5-, 6- or 7-membered, saturated or
unsaturated heterocycles, which may contain nitrogen, oxygen or
sulphur as heteroatoms, for example tetrahydrofuran,
tetrahydrofuranon, .gamma.-butyrolactone, .alpha.-pyran,
.gamma.-pyran, dioxolane, tetrahydropyran, dioxane,
dihydrothiophene, thiolan, dithiolan, pyrroline, pyrrolidine,
pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole,
piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine,
tetrazine, morpholine, thiomorpholine, diazepan, oxazine,
tetrahydro-oxazinyl, isothiazole and pyrazolidine, preferably
pyrazolyl, pyrrolidinyl, piperidinyl, piperazinyl or
tetrahydro-oxazinyl, while the heterocycle may optionally be
substituted.
[0088] Generally, the term halogen denotes fluorine, chlorine,
bromine or iodine.
[0089] The leaving group L denotes either identical or different
leaving groups such as for example chlorine, bromine, iodine,
methanesulphonyl, trifluoromethanesulphonyl or p-toluenesulphonyl,
preferably chlorine.
[0090] The compounds according to the invention may be present in
the form of the individual optical isomers, mixtures of the
individual enantiomers, diastereomers or racemates, in the form of
the tautomers and also in the form of the free bases or the
corresponding acid addition salts with pharmacologically acceptable
acids--such as for example acid addition salts with hydrohalic
acids, for example hydrochloric or hydrobromic acid, or organic
acids, such as for example oxalic, fumaric, diglycolic or
methanesulphonic acid.
[0091] The substituent R.sup.1 may denote a group selected from
among hydrogen, NH.sub.2, XH, preferably OH, halogen, preferably
fluorine or chlorine and a C.sub.1-C.sub.3-alkyl group optionally
substituted by one or more, preferably one, two or three halogen
atoms, preferably fluorine or chlorine, preferably methyl or ethyl.
Most preferably, the substituent R.sup.1 is hydrogen .
[0092] The substituent R.sup.2 may denote a group selected from
among hydrogen, CHO, XH, preferably OH, --X--C.sub.1-C.sub.2-alkyl,
preferably --O--CH.sub.3 or --O--CH.sub.2CH.sub.3, and an
optionally substituted C.sub.1-C.sub.3-alkyl group, while the alkyl
group preferably consists of 1 to 2 carbon atoms, particularly
preferably a carbon atom and may optionally be substituted,
preferably by halogen atoms, most preferably by fluorine atoms. In
particular, the substituent R.sup.2 denotes methyl.
[0093] The substituents R.sup.3 and R.sup.4 may be identical or
different and may represent a group selected from among optionally
substituted C.sub.1-C.sub.10-alkyl, preferably
C.sub.1-C.sub.6-alkyl, preferably C.sub.1-C.sub.4-alkyl, most
preferably methyl, ethyl or propyl, particularly preferably methyl
or ethyl, C.sub.2-C.sub.10-alkenyl, preferably ethenyl or propenyl,
preferably ethenyl, C.sub.2-C.sub.10-alkynyl, preferably ethynyl or
propynyl, aryl, preferably optionally substituted phenyl,
heteroaryl, C.sub.3-C.sub.8-cycloalkyl, preferably cyclopropyl and
cyclobutyl, C.sub.3-C.sub.8-heterocycloalkyl, --X-aryl,
--X-heteroaryl, --X-cycloalkyl, --X-heterocycloalkyl,
--NR.sup.8-aryl, --NR.sup.8-heteroaryl, --NR.sup.8-cycloalkyl and
--NR.sup.8-heterocycloal- kyl, or
[0094] a group selected from among hydrogen, halogen, COXR.sup.8,
CON(R.sup.8).sub.2, COR.sup.8 and XR.sup.8, preferably hydrogen,
or
[0095] the groups R.sup.3 and R.sup.4 may together denote a 2- to
5-membered alkyl bridge, preferably an ethylene, propylene or
butylene bridge , while the propylene or butylene bridge may
contain 1 to 2 heteroatoms, preferably oxygen, nitrogen or sulphur,
most preferably an ethylene bridge.
[0096] Most preferably, the substituent R.sup.3 denotes methyl or
ethyl. The substituent R.sup.4 most preferably denotes hydrogen or
methyl. Particularly preferred are compounds wherein R.sup.3 and
R.sup.4 represent methyl.
[0097] All the groups mentioned in the definition of R.sup.3 and
R.sup.4 may optionally be substituted.
[0098] The group R.sup.5 may contain hydrogen or a group selected
from among optionally substituted C.sub.1-C.sub.10-alkyl, for
example C.sub.1-C.sub.6-alkyl-aryl or
C.sub.1-C.sub.6-alkyl-heteroaryl, preferably C.sub.1-C.sub.6-alkyl,
most preferably C.sub.1-C.sub.5-alkyl, particularly preferably
propyl, butyl, pentyl, hexyl, --CH.sub.2-cyclohexyl,
(CH.sub.2).sub.1-2cyclopropyl or (CH.sub.2).sub.4--OCOCH.sub.3,
C.sub.2-C.sub.10-alkenyl, preferably propenyl, butenyl, pentenyl or
hexenyl, preferably propenyl or hexenyl, C.sub.2-C.sub.10-alkynyl,
preferably propynyl, butynyl or pentynyl, preferably propynyl,
aryl, preferably phenyl, heteroaryl, --C.sub.3-C.sub.6-cycloalkyl,
preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and
-C.sub.3-C.sub.6-cycloalkenyl, preferably cyclohexenyl or
cyclopentenyl, or the substituents R.sup.3 and R.sup.5 or R.sup.4
and R.sup.5 together denote a saturated or unsaturated
C.sub.3-C.sub.4-alkyl bridge which may contain 1 to 2 heteroatoms,
preferably oxygen, sulphur or nitrogen.
[0099] All the groups mentioned in the definition of R.sup.5 may
optionally be substituted.
[0100] The substituent R.sup.6 may denote optionally substituted
aryl, or heteroaryl, preferably aryl, preferably phenyl.
[0101] Most preferably, the substituent R.sup.6 denotes a phenyl
group, which may be substituted by one of the groups R.sup.9 and
R.sup.10 described hereinafter, while the phenyl ring may carry one
of the groups R.sup.9, preferably in the para position, and one,
two, three or four, preferably one or two, of the groups R.sup.10,
preferably in the ortho or meta position.
[0102] The substituent R.sup.7 may denote hydrogen or
--CO--X--C.sub.1-C.sub.4-alkyl, preferably hydrogen.
[0103] X denotes, in each case independently of one another, O or
S, preferably O.
[0104] The groups R.sup.8 mentioned in the definitions of the
substituents R.sup.3 and R.sup.4 represent, independently of one
another in each case, hydrogen or a group selected from among
optionally substituted C.sub.1-C.sub.4-alkyl,
C.sub.2-C.sub.4-alkenyl, C.sub.2-C.sub.4-alkynyl and phenyl,
preferably hydrogen or C.sub.1-C.sub.2-alkyl.
[0105] The substituent R.sup.9 may represent a group selected from
among optionally substituted C.sub.1-C.sub.6-alkyl, preferably
C.sub.1-C.sub.4-alkyl, preferably methyl, ethyl or propyl, most
preferably methyl, C.sub.2-C.sub.6-alkenyl,
C.sub.2-C.sub.6-alkynyl, --CONH--C.sub.1-C.sub.10-alkylene,
preferably --CONH--C.sub.1-C.sub.3-alk- ylene, preferably
--CONH--C.sub.1-C.sub.2-alkylene, --O-aryl, preferably
O--C.sub.6-C.sub.10-aryl, most preferably O-phenyl, --O-heteroaryl,
--O-cycloalkyl, preferably O--C.sub.3-C.sub.6-cycloalkyl, most
preferably O-cyclopropyl, --O-heterocycloalkyl, aryl, preferably
C.sub.6-C.sub.10-aryl, most preferably phenyl, heteroaryl,
cycloalkyl, preferably C.sub.3-C.sub.6-cycloalkyl, most preferably
cyclopropyl, and heterocycloalkyl, or a group selected from among
--O--C.sub.1-C.sub.6-alk- yl-Q.sup.1,
--CONR.sup.8--C.sub.1-C.sub.10-alkyl-Q.sup.1,
--CONR.sup.8--C.sub.1-C.sub.10-alkenyl-Q.sup.1,
--CONR.sup.8Q.sup.2, halogen, for example fluorine, chlorine,
bromine or iodine, OH, --SO.sub.2R.sup.8,
--SO.sub.2N(R.sup.8).sub.2, --COR.sup.8,--COOR.sup.8,
--N(R.sup.8).sub.2, --NHCOR.sup.8,
CONR.sup.8OC.sub.1-C.sub.10-alkylQ.sup- .1 and CONR.sup.8OQ.sup.2,
where Q.sup.1 and Q.sup.2 are as hereinbefore defined.
[0106] Preferably, R.sup.9 denotes one of the following groups
--CONH--C.sub.1-C.sub.10-alkyl, preferably
--CONH--C.sub.1-C.sub.3-alkyl, most preferably
--CONH--C.sub.1-C.sub.2-alkyl, while this alkyl may itself
optionally be substituted, by CN, optionally substituted aryl,
preferably optionally substituted phenyl, heteroaryl, preferably
thienyl, thiazolyl, imidazolyl, pyridyl, pyrimidyl or pyrazinyl,
saturated or unsaturated heterocycloalkyl, preferably pyrazolyl,
pyrrolidinyl, piperidinyl, piperazinyl or tetrahydro-oxazinyl, an
amine group, preferably methylamine, benzylamine, phenylamine or
heteroarylamine, saturated or unsaturated bicyclic ring systems,
preferably benzimidazolyl and cycloalkyl, preferably cyclohexyl.
Moreover R.sup.9 preferably denotes --CONH-heteroaryl, preferably
--CONH-pyridyl, --CONH--C.sub.3-C.sub.10-cycloalkyl, preferably
--CONH-cyclopropyl --CONH-cyclobutyl or --CONH-cyclopentyl, most
preferably --CONH-cyclopropyl;
--CONH--C.sub.3-C.sub.10-heterocycloalkyl,
--CONH--C.sub.6-C.sub.10-aryl, preferably --CONH-phenyl,
COO--C.sub.1-C.sub.3-alkyl, most preferably COOCH.sub.3, COOH,
halogen, preferably F or chlorine, OH or a group of formula 15
[0107] All the groups mentioned in the definition of R.sup.9 may
optionally be substituted, preferably by one or more of the groups
selected from among OH, OCH.sub.3, Cl, F, CH.sub.3, COOH,
CONHCH.sub.2Ph and CONHCH.sub.2-pyrazinyl-CH.sub.3.
[0108] The substituent R.sup.10 may be identical or different in
each case and may denote a group selected from among optionally
substituted C.sub.1-C.sub.6-alkyl , preferably
C.sub.1-C.sub.3-alkyl, C.sub.2-C.sub.6-alkenyl, preferably
C.sub.2-C.sub.3-alkenyl and C.sub.2-C.sub.6-alkynyl, preferably
C.sub.2-C.sub.3-alkynyl, --O--C.sub.1-C.sub.6-alkyl, preferably
--O--C.sub.1-C.sub.3-alkyl, --O--C.sub.2-C.sub.6-alkenyl,
--O--C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-heterocycloalkyl and
C.sub.3-C.sub.6-cycloalkyl, or a group selected from among
hydrogen, --CONH.sub.2, --COOR.sup.8, --OCON(R.sup.8).sub.2,
--N(R.sup.8).sub.2, --NHCOR.sup.8, --NHCON(R.sup.8).sub.2,
--NO.sub.2 and halogen, for example fluorine, chlorine, bromine or
iodine.
[0109] Preferably, the substituent R.sup.10 denotes hydrogen,
methyl, methoxy, fluorine or chlorine, most preferably hydrogen or
methoxy, particularly preferably methoxy.
[0110] Adjacent groups R.sup.9 and R.sup.10 may together denote a
bridge of general formula 16
[0111] wherein
[0112] Y denotes O, S or NR.sup.11, preferably NR.sup.11,
[0113] m denotes 0, 1 or 2, preferably 1,
[0114] R.sup.11 denotes hydrogen or C.sub.1-C.sub.2-alkyl,
preferably hydrogen or methyl, most preferably hydrogen,
[0115] R.sup.12 denotes hydrogen or a group selected from among
optionally substituted phenyl, pyridyl, pyrazinyl, pyrimidinyl,
pyridazinyl, --C.sub.1-C.sub.3-alkyl-phenyl,
--C.sub.1-C.sub.3-alkyl-pyridyl, --C.sub.1-C.sub.3-alkyl-pyrazinyl,
--C.sub.1-C.sub.3-alkyl-pyrimidinyl and
-C.sub.1-C.sub.3-alkyl-pyridazinyl, preferably phenyl, pyridyl and
pyrazinyl, and
[0116] R.sup.13 denotes C.sub.1-C.sub.6-alkyl, preferably methyl or
ethyl.
[0117] The compounds according to the invention may be prepared by
synthesis methods A and B described hereinafter, while the
substituents of general formulae (A1) to (A6) have the meanings
given hereinbefore. These methods are to be understood as
illustrations of the invention without restricting it to their
subject matter.
[0118] Method A
[0119] Step 1A
[0120] A compound of formula (A1) is reacted with a compound of
formula (A2) to obtain a compound of formula (A3) (Diagram 1A).
This reaction may be carried out according to WO 0043369 or WO
0043372. Compound (A1) is commercially obtainable, for example,
from City Chemical LLC, 139 Allings Crossing Road, West Haven,
Conn., 06516, USA. Compound (A2) may be prepared by procedures
known from the literature: (a) F. Effenberger, U. Burkhart, J.
Willfahrt Liebigs Ann. Chem. 1986, 314-333; b) T. Fukuyama, C.-K.
Jow, M. Cheung, Tetrahedron Lett. 1995, 36, 6373-6374; c) R. K.
Olsen, J. Org. Chem. 1970, 35, 1912-1915; d) F. E. Dutton, B. H.
Byung Tetrahedron Lett. 1998, 30, 5313-5316; e) J. M. Ranajuhi, M.
M. Joullie Synth. Commun. 1996, 26, 1379-1384.). 17
[0121] In Step 1A, 1 equivalent of the compound (A1) and 1 to 1.5
equivalents, preferably 1.1 equivalents of a base, preferably
potassium carbonate, potassium hydrogen carbonate, sodium carbonate
or sodium hydrogen carbonate, calcium carbonate, most preferably
potassium carbonate, are stirred in a diluent, for example acetone,
aqueous acetone, tetrahydrofuran, diethylether or dioxane,
preferably acetone or diethylether, most preferably acetone.
[0122] At a temperature of 0 to 15.degree. C., preferably 5 to
10.degree. C., 1 equivalent of an amino acid of formula (A2),
dissolved in an organic solvent, for example acetone,
tetrahydrofuran, diethylether or dioxane, preferably acetone, is
added dropwise.
[0123] The reaction mixture is heated to a temperature of
18.degree. C. to 30.degree. C., preferably about 22.degree. C.,
with stirring and then stirred for a further 10 to 24 hours,
preferably about 12 hours. Then the diluent is distilled off, the
residue is combined with water and the mixture is extracted two to
three times with an organic solvent, such as diethylether or ethyl
acetate, preferably ethyl acetate. The combined organic extracts
are dried and the solvent is distilled off. The residue (compound
A3) may be used in Step 2 without any prior purification.
[0124] Step 2A
[0125] The compound obtained in Step 1A (A3) is reduced at the
nitro group and cyclised to form the compound of formula (A4)
(Diagram 2A). 18
[0126] In Step 2A, 1 equivalent of the nitro compound (A3) is
dissolved in an acid, preferably glacial acetic acid, formic acid
or hydrochloric acid, preferably glacial acetic acid, and heated to
50 to 70.degree. C., preferably about 60.degree. C. Then a reducing
agent, for example zinc, tin or iron, preferably iron filings, is
added to complete the exothermic reaction and the mixture is
stirred for 0.2 to 2 hours, preferably 0.5 hours, at 100 to
125.degree. C., preferably at about 117.degree. C. After cooling to
ambient temperature the iron salt is filtered off and the solvent
is distilled off. The residue is taken up in a solvent or mixture
of solvents, for example ethyl acetate or dichloromethane/methanol
9/1 and semisaturated NaCl solution, and filtered through
kieselgur, for example. The organic phase is dried and evaporated
down. The residue (compound (A4)) may be purified by chromatography
or by crystallisation or used as the crude product in Step 3A of
the synthesis.
[0127] Step 3A
[0128] The compound obtained in Step 2A (A4) may be reacted by
electrophilic substitution as shown in Diagram 3A to obtain the
compound of formula (A5). 19
[0129] In Step 3A 1 equivalent of the amide of formula (A4) is
dissolved in an organic solvent, for example dimethylformamide or
dimethylacetamide, preferably dimethylacetamide, and cooled to
about -5 to 5.degree. C., preferably 0.degree. C. Then 0.9 to 1.3
equivalents of sodium hydride and 0.9 to 1.3 equivalents of alkyl
halide, for example methyl iodide, are added. The reaction mixture
is stirred for 0.1-3 hours, preferably about 1 hour, at about 0 to
10.degree. C., preferably at about 5.degree. C., and may optionally
be left to stand for a further 12 hours at this temperature. The
reaction mixture is evaporated down and extracted with water and an
organic solvent, preferably dichloromethane or ethyl acetate. The
organic phases are evaporated down. The residue (compound (A5)) may
be purified by chromatography, preferably over silica gel.
[0130] Step 4A
[0131] The amination of the compound (A5) obtained in Step 3A to
yield the compound of formula (A7) (Diagram 4A) may be carried out
using the methods known from the literature of variants 4.1 A (a)
M. P. V. Boarland, J. F. W. McOmie J. Chem. Soc. 1951, 1218-1221;
b) F. H. S. Curd, F. C. Rose J. Chem. Soc. 1946, 343-348., 4.2 A
(a) Banks J. Am. Chem. Soc. 1944, 66,1131 b) Ghosh and Dolly J.
Indian Chem. Soc. 1981, 58, 512-513. 20
[0132] For example, in variant 4.1 A, 1 equivalent of the compound
(A5) and 1 to 3 equivalents, preferably about 2 equivalents of the
compound (A6) are heated without a solvent or in an organic solvent
such as for example sulpholane, dimethylformamide,
dimethylacetamide, toluene, N-methylpyrrolidone, dimethylsulphoxide
or dioxane, preferably sulpholane, for 0.1 to 4 hours, preferably 1
hour, at 100 to 220.degree. C., preferably at about 160.degree. C.
After cooling, the product (A7) is crystallised by the addition of
organic solvents or mixtures of solvents, e.g.
diethylether/methanol, ethyl acetate, methylene chloride, or
diethylether, preferably diethylether/methanol 9/1, or purified by
chromatography.
[0133] For example, in variant 4.2 A, 1 equivalent of the compound
(A5) and 1 to 3 equivalents of the compound (A6) are stirred with
acid, for example 1-10 equivalents of 10-38% hydrochloric acid
and/or an alcohol, for example ethanol, propanol, butanol,
preferably ethanol, at reflux temperature for 1 to 48 hours,
preferably about 5 hours.
[0134] The product precipitated (A7) is filtered off and optionally
washed with water, dried and crystallised from a suitable organic
solvent.
[0135] If R.sup.6 denotes an optionally substituted benzimidazole,
the preparation of the compounds (A6) using methods known from the
literature may be carried out as shown in the following diagram,
for example: 21
[0136] Accordingly, for example, 33 mmol of the compound (Z1), 49
mmol of the compound (Z2) and 49 mmol of
1-ethoxycarbonyl-2-ethoxydihydroquinolin- e (EEDQ) are stirred into
50 ml of an organic solvent, preferably dimethylformamide, at about
100 to 130.degree. C., preferably at about 115.degree. C., 1 to 4
hours, preferably about 3 hours. Then the cooled reaction solution
is added to 50 to 400 ml, preferably about 200 ml of a water/ethyl
acetate mixture (mixing ratio about 1:1). The crystals formed (Z3)
are suction filtered and washed.
[0137] Then 4.2 mmol of the compound (Z3) are stirred with 12.5
mmol of tin(II)chloride and 30 mmol of potassium carbonate in about
50 ml of an organic diluent, preferably ethyl acetate, at about
22.degree. C. for 4 to 48 hours, preferably about 24 hours. After
the addition of 22 g of kieselgur the mixture is extracted with an
organic diluent or mixture of diluents, preferably with a mixture
of dichloromethane/methanol (9:1), the combined extracts are
evaporated down and the precipitate formed (Z4) or the crystals
produced (Z4) is or are isolated.
[0138] Step 5A
[0139] If R.sup.9 denotes
--CONR.sup.8--C.sub.1-C.sub.10-alkyl-Q.sup.1,
--CONH--C.sub.1-C.sub.5-alkylene or --CONR.sup.8--Q.sup.2, wherein
the substituents have the meanings given hereinbefore, the
compounds according to the invention may be prepared using methods
known from the literature, for example as shown in Diagram 5A.
[0140] The compound (A7') obtained in Step 4A may be reacted either
by saponification and subsequent amination to obtain the amide of
general formula (A10) (Diagram (5A) variant 5.1 A), or by
saponification, with subsequent conversion into the acid chloride
(A9) and subsequent amination (Diagram (5A) variant 5.2A). 22
[0141] Variant 5.1 A:
[0142] In variant 5.1 A, for example, 20 mmol of the ester (A7')
are heated in about 100 ml of a base, preferably 1N sodium
hydroxide solution or lithium hydroxide solution and about 500 ml
of an alcohol, for example with ethanol, dioxane or methanol,
preferably methanol, until the ester is completely reacted. Then
the alcohol is distilled off. The residue is taken up in about 200
ml of water and acidified while cooling with acid, for example
hydrochloric acid, preferably with 2 N hydrochloric acid. The
product (A8) is filtered off and dried.
[0143] For example, about 0.5 mmol of the compound (A8) are
dissolved with about 0.5 mmol of
O-benzotriazolyl-N,N,N',N'-tetramethyluronium tetrafluoroborate
(TBTU) and about 1.4 mmol of diisopropylethylamine (DIPEA) in about
5 ml of an organic diluent, for example tetrahydrofuran,
dimethylformamide, N-methylpyrrolidone, dimethylacetamide,
preferably dimethylformamide. After the addition of about 0.75 mmol
of an amine which forms the substituent R.sup.9, the reaction
mixture is stirred for 0.1 to 24 hours, preferably about 12 hours
at 20.degree. C. to 100.degree. C. The product of formula (A10) is
obtained for example by crystallisation or chromatographic
purification.
[0144] Variant 5.2 A:
[0145] In variant 5.2 A about 1 mmol of the acid (A8) for example
is suspended in about 2.7 ml of thionyl chloride. The mixture is
heated to 40.degree. C. to 80.degree. C., preferably about
50.degree. C., and at constant temperature 2 to 10 drops,
preferably about 3 drops of dimethylformamide are added to the
reaction mixture with stirring. Then stirring is continued at
90.degree. C. until the reaction is complete. Excess thionyl
chloride is distilled off. About 1 mmol of the acid chloride formed
(A9) are dissolved in about 30 ml of an organic diluent, for
example dichloromethane. After the addition of an amine which forms
the substituent R.sup.9 the mixture is stirred at about 22.degree.
C. The precipitate formed is filtered off and washed with water.
The residue remaining is washed with an organic diluent, for
example methanol. The mother liquor is purified, for example by
chromatography, and evaporated down. The product (A10) remains.
[0146] Method B
[0147] Alternatively to the methods described above, after Step 1A
first the compound (A3) may be aminated and then the product (B1)
may be cyclised to yield the compound (B2), as shown in Diagram B.
Further substitution of the compound (B2) to yield the compound
(A7) may be carried out for example as in Step 3A. 23
[0148] The new compounds of general formula (I) may be synthesised
analogously to the following examples of synthesis. These Examples
are, however, intended only as examples of procedures to illustrate
the invention further, without restricting the invention to their
subject matter.
EXAMPLE 63 AND EXAMPLE 109
[0149] In order to synthesise the compounds 63 and 109, first an
intermediate compound 4 24
[0150] is prepared as described hereinafter.
[0151] 38.9 ml (0.263 mol) of ethyl 2-bromobutyrate and 36.4 g
(0.263 mol) of potassium carbonate were placed in 350 ml of ethyl
acetate, and then 46.7 ml (0.402 mol) of isoamylamine, dissolved in
70 ml of ethyl acetate, were rapidly added dropwise. The mixture
was refluxed for 20 h. The salt formed was filtered off, the
filtrate was concentrated by evaporation, combined with 50 ml of
toluene and again evaporated to dryness.
[0152] Yield: 54.3 g of a compound 1 (red oil)
[0153] 54.3 g of compound 1, dissolved in 400 ml acetone, and 30.7
g (0.222 mol) of potassium carbonate were cooled to 8.degree. C.
with stirring, combined with a solution of 43.1 g (0.222 mol) of
2,4-dichloro-5-nitropyrimidine in 250 ml acetone and then stirred
for 24 h at RT.
[0154] The suspension formed was concentrated by evaporation, the
residue was extracted with water and ethyl acetate, the organic
phase was washed with water and NaCl solution, dried over
MgSO.sub.4 and evaporated to dryness.
[0155] Yield: 87.3 g of a compound 2 (brown oil)
[0156] 44.1 g of compound 2 were dissolved in 800 ml glacial acetic
acid and heated to 65.degree. C. and 36 g of iron filings were
added batchwise. Then the mixture was stirred for 3 h at 70.degree.
C., the precipitate was filtered off and the filtrate was
concentrated by evaporation.
[0157] The residue was applied to silica gel in
dichloromethane/methanol 90:10, concentrated by evaporation and
purified by column chromatography (eluant: ethyl
acetate/cyclohexane 1:1).
[0158] The residue was precipitated from ethyl acetate/petroleum
ether.
[0159] Yield: 16.1 g of a compound 3 (beige powder)
[0160] 16.1 g of compound 3 were dissolved in 75 ml of
dimethylacetamide and cooled to 5.degree. C. under a nitrogen
atmosphere with stirring. Then 2.51 g (0.063 mol) of NaH, 60%
dispersion in mineral oil, was added, whereupon the temperature
temporarily rose to 16.degree. C. After 30 minutes 3.94 ml (0.063
mol) of methyl iodide, dissolved in 75 ml dimethylacetamide, were
added, and the mixture was stirred for 24 h at 22.degree. C.
[0161] The solvent was concentrated by evaporation, combined with
200 ml of water and the precipitate formed was suction filtered,
then extracted by stirring with petroleum ether.
[0162] Yield: 15.1 g of a compound 4 (yellow powder)
[0163] .sup.1H-NMR (250 MHz):=7.80 (1H, s), 4.35 (m, 1H), 3.92 (m,
1H), 3.22 (s, 3H), 3.14 (m, 1H), 1.81 (m, 2H), 1.60-1.40 (m, 3H),
0.90 (m, 6H), 0.70 (t, 3H).
SYNTHESIS OF EXAMPLE 63
[0164] 2.5 g of compound 4, 1.43 g of 4-amino-3-methoxybenzoic
acid, 1.25 mL of conc. hydrochloric acid, 150 mL of dist. water and
37.5 mL of ethanol were refluxed for 10 h. The precipitate was
filtered off, washed with water and extracted by stirring in
methanol. Then the precipitate was recrystallised using petroleum
ether and ether.
[0165] Yield: 1.6 g of a compound 5 (white powder)
[0166] 0.2 g of compound 5, 5 mL of benzylamine, 0.16 g of TBTU,
0.17 g of DIPEA were dissolved in 2 ml of dimethylformamide (DMF)
and stirred for 48 h at ambient temperature. Then the reaction
mixture was taken up in methylene chloride, washed with water and
the organic phase was evaporated down. When petroleum ether/ethyl
acetate 9:1 was added the product was precipitated in the form of
light beige crystals.
[0167] Yield: 0.18 g. Melting point: 178.degree. C.
SYNTHESIS OF EXAMPLE 109
[0168] 5 g of 2 amino-5-nitroaniline, 6.03 g of 4-pyridylcarboxylic
acid, 12.1 g of EEDQ are dissolved in 50 mL of DMF and stirred at
115.degree. C. for 1.75 h, then the DMF is distilled off in vacuo
and the reaction mixture is then heated to 180.degree. C. for 1 h.
The residue is taken up in 30 mL of DMF and combined with 200 mL of
water and 100 mL of ethyl acetate. The crystal slurry obtained is
filtered off and washed with water, ethyl acetate and ether.
[0169] Yield: 5.8 g of a compound 6
[0170] 2 g of the compound 6 is combined with 0.2 g of 5% Pd/C in
30 mL of ethanol and hydrogenated in the presence of hydrogen. It
is then evaporated down and crystallised from ethanol and
toluene.
[0171] Yield: 1.75 g of white powder of a compound 7.
[0172] 0.2 g of the compound 5, 0.28 g of the compound 7, 0.001 g
of sodium-tert. butoxide, 2.5 mL of ethyleneglycol dimethylether,
0.006 g of palladium(II) acetate and 0.22 g of
2-(di-tert.-butylphospino)biphenyl are dissolved in 1.5 mL of
N-methylpyrrolidone (NMP). Then the mixture is heated to
160.degree. C. for 0.5 h. The reaction mixture is then purified
over 20 g of silica gel and the product is crystallised from ether,
ethyl acetate and petroleum ether.
[0173] Yield: 0.04 g of yellow crystals. Melting point: 180.degree.
C.
EXAMPLE 218, 58 AND 4
[0174] In order to synthesise the compounds 218, 58 and 4, first an
intermediate compound 11 25
[0175] is prepared as described hereinafter.
[0176] 55.8 g of DL-alanine methyl ester.times.HCl were dissolved
in 500 ml of methanol, then 76.1 ml of 30% sodium methoxide
solution was added and the salt was filtered off. 37.8 g of
trimethylacetaldehyde were added to the filtrate, then it was left
to stand for 22 h. Then 9.5 g of 10% Pd/C was added and the mixture
was hydrogenated for 3.1 h at 0.5 bar and 20.degree. C. The
reaction mixture was suction filtered through kieselgur and
concentrated by evaporation. The residue was taken up in
diethylether, the salts were filtered through kieselgur and the
filtrate was concentrated by evaporation.
[0177] Yield: 55.8 g of a compound 8 (clear liquid)
[0178] 48.5 g of 2,4-dichloro-5-nitropyrimidine were placed in 400
ml of diethylether, 41.0 g of potassium hydrogen carbonate in 400
ml of water were added, and the mixture was cooled to -5.degree. C.
43.3 g of compound 8 were dissolved in 400 ml of diethylether and
added dropwise at -5.degree. C. The mixture was stirred for 1 h at
-5.degree. C. and for 2 h at 0.degree. C., then heated to ambient
temperature and the reaction mixture was left to stand for 24
h.
[0179] The organic phase was separated off, dried over MgSO.sub.4
and evaporated to dryness.
[0180] Yield: 79.2 g of a compound 9 (yellow resin)
[0181] 79.0 g of compound 9 were dissolved in 1000 ml of glacial
acetic acid and heated to 70.degree. C. After the removal of the
heat source 52 g of iron was added batchwise. The temperature rose
to about 110.degree. C. and the mixture was stirred for 1 h at this
temperature. The suspension was filtered while hot and the filtrate
was concentrated by evaporation.
[0182] The residue was taken up in ethyl acetate and combined with
150 ml of conc. HCl, the organic phase was separated off and the
aqueous phase extracted several times with dichloromethane. The
combined organic phases were concentrated by evaporation, applied
to silica gel and purified by column chromatography (eluant:
petroleum ether/ethyl acetate 1:1).
[0183] As the isolated substance was still highly contaminated, it
was again purified over silica gel. The desired compound
crystallised out, the crystals were suction filtered. The mother
liquor was concentrated by evaporation and recrystallised from
ethyl acetate/diethylether.
[0184] Yield: 17.63 g of a compound 10
[0185] 7.6 g of the compound 10 and 6.4 ml of methyl iodide were
placed in 75 ml of dimethylacetamide (DMA) and cooled to
-15.degree. C. 1.25 g of NaH, 60% dispersion in mineral oil, was
added batchwise, and stirred for 30 min. at -10.degree. to
-5.degree. C. Then 150 ml of ice water were added, the crystals
were suction filtered and washed with water and petroleum ether.
The crystals were taken up in dichloromethane, filtered through
kieselgur and the filtrate was evaporated to dryness. It was
recrystallised from petroleum ether.
[0186] Yield: 6.3 g of compound 11 (beige crystals) .sup.1H-NMR
(250 MHz):=7.73 (1H, s), 4.35 (d, 1H), 4.25 (m, 1H), 3.35 (s, 3H),
2.55 (d, 1H), 1.31 (d, 3H), 0.95 (s, 9H).
SYNTHESIS OF EXAMPLE 218
[0187] 0.2 g of compound 11, 3,5-difluoro-4-hydroxyaniline and 0.75
mL of sulpholane were heated to 130.degree. C. for 15 min, to
140.degree. C. for 15 min and to 170.degree. C. for 10 min. Then
the mixture was combined with ether, the supernatant solution was
decanted off and the residue was crystallised from methanol/ether
and recrystallised again from methanol.
[0188] Yield: 0.15 g of white crystals. Melting
point:>250.degree. C.
SYNTHESIS OF EXAMPLE 4
[0189] 6.3 g of compound 11 were dissolved in 25 mL of sulpholane
at 100.degree. C., then combined with 4.0 g of ethyl
4-aminobenzoate and heated to 170.degree. C. for 1 h. Then the
mixture was combined with 50 mL of ether. After crystallisation
started, a further 50 mL of ether and 50 mL of methanol were added.
The crystals were recrystallised from methanol.
[0190] Yield: 6.6 g of a compound 12 (yellowish crystals), melting
point: from 65.degree. C. decomposition sets in
[0191] 3.55 g of compound 12 were suspended in 250 mL of methanol
and at 60.degree. C. combined with 25 mL of 4N sodium hydroxide
solution. After 6 h, 15 mL of glacial acetic acid were added, the
resulting crystals were filtered off and washed with
methanol/ether.
[0192] Yield: 1.2 g of a compound 13 (white crystals)
[0193] 1.5 g of compound 13 were dissolved in 7.5 mL of thionyl
chloride and heated to 80.degree. C. for 1 h. Then the thionyl
chloride was eliminated by distillation, the residue was stirred
with ether, the crystals were suction filtered and washed with
ether.
[0194] Yield: 1.7 g of a compound 14 (yellow crystals)
[0195] 0.18 g of 3-aminopyridine were dissolved in 10 mL of
tetrahydrofuran (THF) and combined with 0.4 mL of triethylamine.
Then 0.22 g of compound 14 were added and the mixture was stirred
for 16 h at ambient temperature. The mixture was evaporated to
dryness, taken up in ethyl acetate, extracted with water,
evaporated down again and the product was crystallised from ethyl
acetate.
[0196] Yield: 0.07 g (beige crystals), Melting point:
215-216.degree. C.
SYNTHESIS OF EXAMPLE 58
[0197] 0.05 g of compound 13 were suspended in 10 mL of
dichloromethane, then combined with 0.15 mL of DIPEA and 0.05 g of
TBTU. The solution was then stirred for 30 min and combined with
0.01 mL of 4-picolylamine. After 18 h the mixture was combined with
20 mL of water, the organic phase was separated off and the product
was purified by silica gel chromatography, then recrystallised from
ethyl acetate/petroleum ether.
[0198] Yield: 0.044 g (white crystals), Melting point:
238-240.degree. C.
EXAMPLES 65 AND 125
[0199] In order to synthesise the compounds 65 and 125, first an
intermediate compound 18 26
[0200] is prepared as described hereinafter.
[0201] 28.3 g of isobutylamine, 36 g of ethyl R,S-2-bromopropionate
and 28 g of potassium carbonate were refluxed in 150 ml of ethyl
acetate for 6 h. After cooling the salt was suction filtered, the
mother liquor was concentrated by evaporation.
[0202] The residue was combined with 100 ml of toluene and
evaporated to dryness.
[0203] Yield: 37.2 g of a compound 15 (yellow oil)
[0204] 38.4 g of 2,4-dichloro-5-nitropyrimidine were placed in 300
ml of diethylether, 30 g of potassium hydrogen carbonate in 300 ml
of water were added and the mixture was cooled to 0.degree. C. 37.0
g of compound 15 were dissolved in 300 ml of diethylether and added
dropwise at 0.degree.-3.degree. C. After 3 h the phases were
separated, the organic phase was dried and evaporated to
dryness.
[0205] Yield: 71.6 g of a compound 16
[0206] 40.0 g of compound 16 were dissolved in 300 ml of glacial
acetic acid and heated to 70.degree. C. After removal of the heat
source, 30 g of iron was added batchwise. The temperature rose to
110.degree. C. The reaction mixture was cooled to 90.degree. C. and
stirred for 20 min. at this temperature. Then it was filtered while
hot and the filtrate was concentrated by evaporation. The residue
was stirred with 300 ml of water and 300 ml of dichloromethane and
filtered through kieselgur. The phases were separated. The organic
phase was washed with water, dried over MgSO.sub.4 and evaporated
to dryness. It was extracted from petroleum ether.
[0207] Yield: 26.7 g of a compound 17
[0208] 15.0 g of compound 17 were placed in 100 ml of DMA, 4.13 ml
of methyl iodide were added and the mixture was cooled to 5.degree.
C. 2.60 g of NaH were added batchwise as a 60% dispersion in
mineral oil. The temperature rose to 13.degree. C. After 30 min.
300 ml of ice water were added, the crystals precipitated were
suction filtered and washed with petroleum ether.
[0209] Yield: 13.9 g of a compound 18 .sup.1H-NMR (250 MHz):=7.95
(1H, s), 4.30 (m, 1H), 3.95 (m, 1H), 3.24 (s, 3H), 2.95 (m, 1H),
2.05 (m, 1H), 1.30 (d, 3H), 0.96 (d, 3H), 0.92 (d, 3H).
SYNTHESIS OF EXAMPLE 65
[0210] 2.1 g of compound 18 were combined with ethyl
4-aminobenzoate in 10 mL sulpholane and stirred for 2 h at
160.degree. C. Then ether was added and the crystals precipitated
were washed with ether:
[0211] Yield: 3.0 g of a compound 19
[0212] 3 g of the compound 19 were combined with 200 mL of methanol
and 25 mL of 4N NaOH and stirred for 4 h at 60.degree. C. Then
glacial acetic acid was added, the crystals precipitated were
filtered off and washed with ether.
[0213] Yield: 2.3 g of a compound 20 (white crystals)
[0214] 0.1 g of compound 20 were suspended in 3 mL of
dichloromethane and 3 mL of DMF, and then combined with 0.13 g of
DIPEA, 0.095 g of TBTU and 0.045 g of hydroxybenzotriazole (HOBt).
Then the solution was stirred for 30 min and combined with 0.035 g
of N-methyl-3-picolylamine. After 0.5 h the mixture was combined
with water and 1 g of potassium carbonate, the aqueous phase was
extracted twice with 50 mL of ethyl acetate and the product was
purified by silica gel chromatography and then recrystallised from
ethanol/acetone.
[0215] Yield: 0.08 g
SYNTHESIS OF EXAMPLE 125
[0216] 3.7 g of compound 20, 3.8 g of TBTU, 1.6 g of HOBt, 5 mL of
DIPEA were dissolved in 40 mL of DMF and stirred for 4 h at ambient
temperature. The mixture was evaporated down, taken up in 200 mL of
ethyl acetate and extracted twice with 5 mL of 5% potassium
carbonate solution. The organic phase was evaporated down, the
crystals precipitated were filtered off and washed with ethyl
acetate and ether.
[0217] Yield: 1.65 g of a compound 21 (yellowish crystals)
[0218] 0.486 g of compound 21 were refluxed with 0.33 g of
1,2-phenylenediamine in 10 mL of toluene for 0.5 h, then the
mixture was evaporated down. The residue was combined with 100 mL
ethyl acetate, the organic phase was extracted twice with water.
The organic phase was evaporated down, the crystals precipitated
were suction filtered and washed with a little ethyl acetate.
[0219] Yield: 0.25 g of a compound 22 (white crystals)
[0220] 0.22 g of compound 22 were stirred into 20 g of
polyphosphoric acid for 0.5 h at 150.degree. C., then the mixture
was poured onto ice and ammonia was added. It was then extracted
twice with 100 mL of ethyl acetate, the organic phase was washed
with water and evaporated down. The precipitated product (crystals)
was suction filtered and washed with ethyl acetate and ether.
[0221] Yield: 0.115 g of yellowish crystals, Melting point:
287.degree. C. (decomposition)
EXAMPLE 171
[0222] In order to synthesise compound 171 first an intermediate
compound 27 [sic] 27
[0223] 34.4 g of N-isopentyl-benzylamine, 36.2 g of ethyl
2-bromo-propionate and 42.0 g of potassium carbonate were placed in
250 ml of DMF and stirred for 3 h at 110.degree. C. After cooling
the inorganic salts were filtered off, the filtrate was
concentrated by evaporation. The residue was extracted with water
and diethylether, the organic phase was washed with water, dried
and evaporated to dryness.
[0224] Yield: 55.5 g of a compound 23
[0225] 55.5 g of compound 23 were placed in 600 ml of ethanol, and
hydrogenated with 20 ml of 32% HCl and 6 g of 10% Pd/C at
20.degree. C. under 5 bar for 20 min. Then it was filtered through
kieselgur and concentrated by evaporation. The residue was combined
with 400 ml of diethylether, the precipitate was suction filtered
and washed with diethylether.
[0226] Yield: 23.5 g of a compound 24, melting point 105.degree.
C.
[0227] 23.5 g of compound 24 were dissolved in 200 ml of water and
combined with 20.0 g (0.103 mol) of 2,4-dichloro-5-nitropyrimidine
in 400 ml of diethylether. After the reaction mixture had been
cooled to -10.degree. C., 50.0 g (0.499 mol) of potassium carbonate
were added batchwise. The mixture was stirred at -5.degree. C. for
1 h and at 0.degree. C. for 1 h, then heated to ambient
temperature. The aqueous phase was separated off, the organic phase
was washed with water, dried and evaporated to dryness.
[0228] Yield: 36.9 9 of a compound 25
[0229] 20.0 g of the compound 25 were dissolved in 280 ml of
glacial acetic acid and heated to 70.degree. C. After removal of
the heat source 17 g of iron were added. The temperature rose to
100.degree. C., then the mixture was stirred for 30 min. at this
temperature.
[0230] It was then filtered while hot and the filtrate was
concentrated by evaporation. The residue was combined with 300 ml
of dichloromethane and 30 ml of 32% HCl, the phases were separated,
the aqueous phase was extracted with dichloromethane, the combined
organic phases were washed with water and aqueous ammonia solution,
dried and evaporated to dryness. The residue was extracted with
diethylether.
[0231] Yield: 10.5 g of a compound 26, melting point:
182.degree.-185.degree. C.
[0232] 2.7 g of the compound 26 and 2.5 ml of methyl iodide were
placed in 27 ml of DMA and cooled to -10.degree. C. 0.45 g of NaH,
60% dispersion in mineral oil, was added and stirred for 30 min. at
-5.degree. C. Then 10 g of ice and 5 ml of 2N HCl were added and
the mixture was concentrated by evaporation. The residue was
extracted with ethyl acetate and water, the organic phase was
dried, evaporated to dryness and filtered through silica gel.
[0233] Yield: 3.0 g of compound 27 (oil) .sup.1H-NMR (250
MHz):=7.67 (1H, s), 4.32-4.07 (m, 2H), 3.32 (s, 3H), 3.08 (m, 1H),
1.70-1.50 (m, 3H), 1.42 (d, 3H), 0.95 (m, 6H).
SYNTHESIS OF EXAMPLE 171
[0234] 0.28 g of compound 27, 0.9 mL of sulpholane and 0.22 g of
p-aminobenzoic acid-benzylamide were stirred for 0.5 h at
170.degree. C., then the mixture was combined with ether and the
crystals were filtered off. The product was recrystallised from
ethanol.
[0235] Yield: 0,15 g, melting point: 228-240.degree. C. (yellowish
crystals)
[0236] The compounds of formula (I) listed in Table 1 are obtained
analogously to the process described above.
[0237] The abbreviations X.sub.2, X.sub.3, X.sub.4, X.sub.5 and
X.sub.6 used in Table 1 in each case denote a link to a position in
the general formula shown under Table 1 instead of the
corresponding groups R.sup.2, R.sup.3, R.sup.4, R.sup.5 and
R.sup.6.
1TABLE 1 28 config. mp. Ex. R.sup.2 R.sup.3 R.sup.4 R.sup.3 or
R.sup.4 R.sup.5 R.sup.6 [.degree. C.] 1 29 H H rac. 30 31 2 32 33 H
rac. 34 35 208 3 36 37 H rac. 38 39 241 4 40 41 H rac. 42 43 5 44
45 H rac. 46 47 175 6 48 49 H R 50 51 190 7 52 53 H rac. 54 55 8 56
57 H rac. 58 59 200 9 60 61 H rac. 62 63 168 10 64 65 H rac. 66 67
190 11 68 69 H rac. 70 71 12 72 73 H rac. 74 75 13 76 77 H rac. 78
79 145 14 80 81 H rac. 82 83 15 84 85 H rac. 86 87 55 16 88 89 H
rac. 90 91 250 17 92 93 H rac. 94 95 204 18 96 97 H rac. 98 99 19
100 101 H rac. 102 103 20 104 105 H R 106 107 221 21 108 109 H rac.
110 111 172 22 112 113 H rac. 114 115 221 23 116 117 H rac. 118 119
24 120 121 H rac. 122 123 210 25 124 125 H R 126 127 213 26 128 129
H rac. 130 131 188 27 132 133 H rac. 134 135 28 136 137 H S 138 139
29 140 141 H rac. 142 143 178 30 144 145 H R 146 147 175 31 148 149
H rac. 150 151 32 152 153 H rac. 154 155 221 33 156 157 H R 158 159
124 34 160 161 H rac. 162 163 136 35 164 165 H rac. 166 167 162 36
168 169 H rac. 170 171 169 37 172 173 H rac. 174 175 219 38 176 177
H rac. 178 179 179 39 180 181 H rac. 182 183 211 40 184 185 H rac.
186 187 41 188 189 H rac. 190 191 42 192 193 H R 194 195 100 43 196
197 H rac. 198 199 175 44 200 201 H rac. 202 203 203 45 204 205 H
rac. 206 207 165 46 208 209 H rac. 210 211 47 212 213 H rac. 214
215 48 216 217 H rac. 218 219 49 220 221 H rac. 222 223 50 224 225
H rac. 226 227 212 51 228 229 H S 230 231 52 232 233 H rac. 234 235
53 236 237 H rac. 238 239 54 240 241 H rac. 242 243 55 244 245 H
rac. 246 247 191 56 248 249 H rac. 250 251 158 57 252 253 H rac.
254 255 230 58 256 257 H rac. 258 259 59 260 261 H R 262 263 125 60
264 H H rac. 265 266 250 61 267 268 H rac. 269 270 62 271 272 H
rac. 273 274 169 63 275 276 H rac. 277 278 178 64 279 280 H rac.
281 282 65 283 284 H rac. 285 286 66 287 288 H R 289 290 225 67 291
292 H rac. 293 294 68 295 296 H rac. 297 298 69 299 300 H rac. 301
302 70 303 304 H rac. 305 306 71 307 308 H rac. 309 310 72 311 312
H rac. 313 314 73 315 316 H rac. 317 318 74 319 320 321 322 167 75
323 324 H rac. 325 326 76 327 328 H rac. 329 330 246 77 331 332 H
rac. 333 334 78 335 336 H rac. 337 338 172 79 339 340 H rac. 341
342 170 80 343 344 345 rac. 346 347 222 81 348 349 H rac. 350 351
187 82 352 353 H rac. 354 355 215 83 356 357 358 359 199 84 360 361
362 rac. 363 364 127 85 365 366 H rac. 367 368 86 369 370 H rac.
371 372 169 87 373 374 H rac. 375 376 250 88 377 378 H rac. 379 380
233 89 381 382 H rac. 383 384 160 90 385 386 H rac. 387 388 154 91
389 390 H rac. 391 392 92 393 394 H rac. 395 396 93 397 398 H rac.
399 400 94 401 402 H R 403 404 95 405 406 H rac. 407 408 150 96 409
410 411 rac. 412 413 300 97 414 415 H rac. 416 417 243 98 418 419 H
rac. 420 421 209 99 422 423 H rac. 424 425 182 100 426 427 H rac.
428 429 101 430 431 H R 432 433 232 102 434 435 H rac. 436 437 103
438 439 H rac. 440 441 104 442 443 H rac. 444 445 146 105 446 447 H
rac. 448 449 209 106 450 451 H rac. 452 453 286 107 454 455 H rac.
456 457 108 458 459 H R 460 461 202 109 462 463 H rac. 464 465 180
110 466 467 H rac. 468 469 111 470 471 H rac. 472 473 250 112 474
475 H rac. 476 477 113 478 479 H rac. 480 481 114 482
X.sub.3--CH.sub.3 483 484 485 237 115 486 487 H rac. 488 489 135
116 490 491 H rac. 492 493 117 494 495 H rac. 496 497 118 498 499 H
rac. 500 501 119 502 503 H rac. 504 505 213 120 506 507 H rac. 508
509 198 121 510 511 H rac. 512 513 122 514 515 H rac. 516 517 123
518 519 H rac. 520 521 124 522 523 H rac. 524 525 125 526 527 H
rac. 528 529 287 126 530 531 H rac. 532 533 127 534 535 H rac. 536
537 128 538 539 H rac. 540 541 129 542 543 H rac. 544 545 247 130
546 547 H rac. 548 549 131 550 X.sub.3--CH.sub.3 551 552 553 281
132 554 555 H rac. 556 557 133 558 559 H rac. 560 561 134 562 563 H
rac. 564 565 208 135 566 567 H rac. 568 569 136 570 571 H R 572 573
192 137 574 575 H rac. 576 577 212 138 578 579 H rac. 580 581 139
582 583 H rac. 584 585 140 586 587 H rac. 588 589 148 141 590 591 H
rac. 592 593 142 594 595 H rac. 596 597 143 598 599 H rac. 600 601
186 144 602 603 604 605 199 145 606 607 H rac. 608 609 214 146 610
611 H rac. 612 613 155 147 614 615 H rac. 616 617 148 618 619 H
rac. 620 621 149 622 623 H rac. 624 625 245 150 626 627 H rac. 628
629 151 630 631 H rac. 632 633 152 634 635 H rac. 636 637 153 638
639 H rac. 640 641 154 642 643 H rac. 644 645 155 646 647 H rac.
648 649 156 650 651 H rac. 652 653 265 157 654 655 H rac. 656 657
192 158 658 659 H rac. 660 661 222 159 662 663 H rac. 664 665 221
160 666 667 668 669 670 298 161 671 672 H rac. 673 674 181 162 675
676 H S 677 678 163 679 680 681 682 172 164 683 684 H rac. 685 686
227 165 687 688 H rac. 689 690 258 166 691 X.sub.3--CH.sub.3 692
693 694 266 167 695 696 H rac. 697 698 168 699 700 701 rac. 702 703
159 169 704 705 706 707 250 170 708 709 H rac. 710 711 213 171 712
713 H rac. 714 715 228 172 716 717 H rac. 718 719 181 173 720 721 H
rac. 722 723 182 174 724 725 H rac. 726 727 175 728 729 H rac. 730
731 197 176 732 733 H rac. 734 735 177 736 737 H rac. 738 739 216
178 740 741 H rac. 742 743 200 179 744 745 H rac. 746 747 197 180
748 749 750 rac. 751 752 143 181 753 754 755 756 234 182 757 758 H
rac. 759 760 183 761 762 H rac. 763 764 169 184 765 766 H rac. 767
768 185 769 770 H rac. 771 772 198 186 773 774 775 776 202 187 777
778 H rac. 779 780 200 188 781 782 H rac. 783 784 189 785 786 H
rac. 787 788 198 190 789 790 791 792 196 191 793 X.sub.3--CH.sub.3
794 795 796 253 192 797 798 H rac. 799 800 193 801 802 H rac. 803
804 201 194 805 806 H rac. 807 808 250 195 809 810 H rac. 811 812
198 196 813 814 H rac. 815 816 245 197 817 818 H rac. 819 820 198
821 822 H rac. 823 824 199 825 826 H rac. 827 828 200 829
X.sub.3--CH.sub.3 830 831 832 198 201 833 H H rac. 834 835 202 836
837 H rac. 838 839 203 840 841 H rac. 842 843 198 204 844 845 H
rac. 846 847 205 848 849 H rac. 850 851 206 852 853 H rac. 854 855
207 856 857 H rac. 858 859 184 208 860 861 H rac. 862 863 253 209
864 865 H rac. 866 867 240 210 868 869 H rac. 870 871 211 872
X.sub.3--CH.sub.3 873 874 875 266 212 876 877 H rac. 878 879 213
880 881 H rac. 882 883 214 884 885 H rac. 886 887 215 888 889 H
rac. 890 891 232 216 892 893 H rac. 894 895 217 896 897 H rac. 898
899 218 900 901 H rac. 902 903 >250 219 904 905 H rac. 906 907
260 (Zers.) 220 908 909 H R 910 911 190 221 912 913 H R 914 915 228
222 916 917 H R 918 919 223 920 921 H R 922 923 243 224 924 925 H R
926 927 258 225 928 929 H R 930 931 226 932 933 H R 934 935 227 936
937 H R 938 939 241 228 940 941 H R 942 943 229 944 945 H R 946 947
300 230 948 949 H R 950 951 200 231 952 953 H R 954 955 232 232 956
957 H R 958 959 149 234 960 961 H R 962 963 197 235 964 965 H R 966
967 226 236 968 969 H R 970 971 182 237 972 973 H R 974 975 238 976
977 H R 978 979 239 980 981 H R 982 983 240 984 985 H R 986 987 241
988 989 H R 990 991 194 242 992 993 H R 994 995 200 243 996 997 H R
998 999 156 244 1000 1001 H R 1002 1003 195 245 1004 1005 H R 1006
1007 147 246 1008 1009 H R 1010 1011 247 1012 1013 H R 1014 1015 85
248 1016 1017 H R 1018 1019 249 1020 1021 H R 1022 1023 250 1024
1025 H R 1026 1027 158 251 1028 1029 H R 1030 1031 188 252 1032
1033 H R 1034 1035 245 253 1036 1037 H R 1038 1039 254 1040 1041 H
R 1042 1043 128 255 1044 1045 H R 1046 1047 256 1048 1049 H R 1050
1051 181 257 1052 1053 H R 1054 1055 217 258 1056 1057 H R 1058
1059 259 1060 1061 H R 1062 1063 260 1064 1065 H R 1066 1067 261
1068 1069 H R 1070 1071 230 262 1072 1073 H R 1074 1075 193 263
1076 1077 H R 1078 1079 264 1080 1081 H R 1082 1083 152 265 1084
1085 H R 1086 1087 207 266 1088 1089 H R 1090 1091 229 267 1092
1093 H R 1094 1095 268 1096 1097 H R 1098 1099 183 269 1100 1101 H
R 1102 1103 270 1104 1105 H R 1106 1107 161 271 1108 1109 H R 1110
1111 282 272 1112 1113 H R 1114 1115 157 273 1116 1117 H R 1118
1119 129 274 1120 1121 H R 1122 1123 164 275 1124 1125 H R 1126
1127 219 276 1128 1129 H R 1130 1131 277 1132 1133 H R 1134 1135
200 278 1136 1137 H R 1138 1139 200 279 1140 1141 H R 1142 1143 280
1144 1145 H R 1146 1147 281 1148 1149 H R 1150 1151 282 1152 1153 H
R 1154 1155 283 1156 1157 H R 1158 1159 277 284 1160 1161 H R 1162
1163 197 285 1164 1165 H R 1166 1167 286 1168 1169 H R 1170 1171
182 287 1172 1173 H R 1174 1175 288 1176 1177 H R 1178 1179 163 289
1180 1181 H R 1182 1183 212 290 1184 1185 H R 1186 1187 291 1188
1189 H R 1190 1191 292 1192 1193 H R 1194 1195 293 1196 1197 H R
1198 1199 200 294 1200 1201 H R 1202 1203 144 295 1204 1205 H R
1206 1207 221 296 1208 1209 H R 1210 1211 150 297 1212 1213 H R
1214 1215 298 1216 1217 H R 1218 1219 163 299 1220 1221 H R 1222
1223 300 1224 1225 H R 1226 1227 98 301 1228 1229 H R 1230 1231 302
1232 1233 H R 1234 1235 303 1236 1237 H R 1238 1239 304 1240 1241 H
R 1242 1243 305 1244 1245 H R 1246 1247 306 1248 1249 H R 1250 1251
307 1252 1253 H R 1254 1255 179 308 1256 1257 H R 1258 1259 174 309
1260 1261 H R 1262 1263 231 310 1264 1265 H R 1266 1267 311 1268
1269 H R 1270 1271 312 1272 1273 H R 1274 1275 313 1276 1277 H R
1278 1279 314 1280 1281 H R 1282 1283 69 315 1284 1285 H R 1286
1287 200 316 1288 1289 H R 1290 1291 210 317 1292 1293 H R 1294
1295 131 318 1296 1297 H R 1298 1299 319 1300 1301 H R 1302 1303
145 320 1304 1305 H R 1306 1307 321 1308 1309 H R 1310 1311 322
1312 1313 H R 1314 1315 149 323 1316 1317 H R 1318 1319 324 1320
1321 H R 1322 1323 325 1324 1325 H R 1326 1327 326 1328 1329 H R
1330 1331 327 1332 1333 H R 1334 1335 328 1336 1337 H R 1338 1339
176 329 1340 1341 H R 1342 1343 330 1344 1345 H R 1346 1347 331
1348 1349 H R 1350 1351 332 1352 1353 H R 1354 1355 333 1356 1357 H
R 1358 1359 334 1360 X.sub.3--CH.sub.3 1361 1362 1363 250 335 1364
X.sub.3--CH.sub.3 1365 1366 1367 236 In the preceding Table the
abbreviations X1 to X6 in the groups specified denote the bond
which links the particular group to the corresponding group R1 to
R6.
[0238] As has been found, the compounds of general formula (I) are
characterised by their wide range of applications in the
therapeutic field. Particular mention should be made of those
applications in which the inhibition of specific cell cycle
kinases, particularly the inhibiting effect on the proliferation of
cultivated human tumour cells but also the proliferation of other
cells, such as endothelial cells, for example, plays a part.
[0239] As could be demonstrated by FACS analysis, the inhibition of
proliferation brought about by the compounds according to the
invention is mediated by the arrest of the cells, particularly at
the G2/M phase of the cell cycle. The cells arrest, independently
of the cells used, for a specific length of time in this phase of
the cell cycle before programmed cell death is initiated. An arrest
in the G2/M phase of the cell cycle is triggered, for example, by
the inhibition of specific cell cycle kinases. Studies in model
organisms such as Schizosaccharomyces pombe or Xenopus, or
investigations in human cells have shown that the transition from
the G2 phase to mitosis is regulated by the CDK1/cyclin B kinase
(Nurse, 1990). This kinase, which is also known as the "mitosis
promoting factor" (MPF), phosphorylates and thereby regulates a
number of proteins, such as e.g. nuclear lamins, kinesin-like motor
proteins, condensins and Golgi matrix proteins, which play an
important part in the breakdown of the nuclear envelope, in
centrosome separation, the formation of the mitotic spindle
apparatus, chromosome condensation and the breakdown of the Golgi
apparatus (Nigg. E., 2001). A murine cell line with a
temperature-sensitive CDK1 kinase mutant shows a rapid breakdown of
the CDK1 kinase and a subsequent arrest in the G2/M phase after a
temperature increase (Th'ng et al., 1990). The treatment of human
tumour cells with inhibitors against CDK1/cyclin B such as e.g.
butyrolactone also leads to an arrest in the G2/M phase and
subsequent apoptosis (Nishio, et al. 1996). Another kinase which is
involved in the G2 and mitosis phase is polo-like kinase 1 (Plk1),
which is responsible for the maturation of the centrosomes, for the
activation of the phosphatase Cdc25C, as well as for the activation
of the anaphase promoting complex (Glover et al., 1998, Qian, et
al., 2001). The injection of Plk1 antibodies leads to a G2 arrest
in untransformed cells whereas tumour cells arrest in the mitosis
phase (Lane and Nigg, 1996). In addition, the protein kinase aurora
B has been described as having an essential function during entry
into mitosis. Aurora B phosphorylates histone H3 at Ser11 and
thereby initiates chromosome condensation (Hsu, J. Y. et al.,
2000). A specific cell cycle arrest in the G2/M phase may, however,
also be triggered e.g. by the inhibition of specific phosphatases
such as e.g. Cdc25C (Russell and Nurse, 1986). Yeasts with a
defective cdc25 gene arrest in the G2 phase, while overexpression
of cdc25 leads to early entry into the mitosis phase (Russell and
Nurse, 1987). However, an arrest in the G2/M phase can also be
triggered by the inhibition of certain motor proteins, so-capped
kinesins such as e.g. Eg5 (Mayer et al., 1999), or by agents which
stabilise or destabilise microtubules (e.g. colchicin, taxol,
etoposide, vinblastin, vincristin) (Schiff and Horwitz, 1980).
[0240] In view of their biological properties the compounds of
general formula I according to the invention, their isomers and
their physiologically acceptable salts are suitable for the
treatment of diseases characterised by excessive or abnormal cell
proliferation.
[0241] Such diseases include, for example: viral infections (e.g.
HIV and Kaposi's sarcoma); inflammatory and autoimmune diseases
(e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis
and wound healing); bacterial, fungal and/or parasitic infections;
leukaemias, lymphoma and solid tumours; skin diseases (e.g.
psoriasis); bone diseases; cardiovascular diseases (e.g. restenosis
and hypertrophy). They are also suitable for protecting
proliferating cells (e.g. hair, intestinal, blood and progenitor
cells) from damage to their DNA caused by radiation, UV treatment
and/or cytostatic treatment (Davis et al., 2001).
[0242] The new compounds may be used for the prevention, short-term
or long-term treatment of the abovementioned diseases, also in
combination with other active substances used for the same
indications, e.g. cytostatics.
[0243] The activity of the compounds according to the invention was
determined in the cytotoxicity test on cultivated human tumour
cells and/or in a FACS analysis, for example on HeLaS3 cells. In
both test methods, the compounds exhibited a good to very good
activity, i.e. for example an EC.sub.50 value in the HeLaS3
cytotoxicity test of less than 5 .mu.mol, generally less than 1
.mu.mol.
[0244] Measurement of Cytotoxicity on Cultivated Human Tumour
Cells
[0245] To measure the cytotoxicity on cultivated human tumour
cells, cells of the cervical cancer tumour cell line HeLaS3
(obtained from American Type Culture Collection (ATCC)) in Ham's
F12 Medium (Life Technologies) and 10% foetal calf serum (Life
Technologies) were cultivated and harvested in the logarithmic
growth phase. Then the HeLaS3 cells were placed in 96-well plates
(Costar) at a density of 1000 cells per well and incubated
overnight in an incubator (at 37.degree. C. and 5% CO.sub.2), while
on each plate 6 wells were filled only with medium (3 wells as a
control of the medium, 3 wells for incubation with reduced
AlamarBlue). The active substances were added to the cells in
various concentrations (dissolved in DMSO; final concentration: 1%)
(in each case as a triple measurement). After 72 hours' incubation,
20 .mu.l of AlamarBlue (AccuMed International) were added to each
well, and the cells were incubated for a further 7 hours. As a
control, 20 .mu.l of reduced Alamar Blue (AlamarBlue reagent which
had been autoclaved for 30 min) were added to 3 wells. After 7 h
incubation the colour change of the AlamarBlue reagent in the
individual wells was determined in a Perkin Elmer fluorescence
spectrophotometer (excitation 530 nm, emission 590 nm, slits 15,
integrate time 0.1). The amount of AlamarBlue reagent reacted
represents the metabolic activity of the cells. The relative cell
activity was calculated as a percentage of the control (HeLa S3
cells without inhibitor) and the active substance concentration
which inhibits the cell activity by 50% (IC.sup.50) was obtained.
The values were calculated from the average of three individual
measurements, correcting for the control value (medium
control).
[0246] FACS Analysis
[0247] Propidium iodide (PI) binds stoichiometrically to
double-stranded DNA, and is thus suitable for determining the
percentage of cells in the G1, S and G2/M phase of the cell cycle
on the basis of the cell DNA content. Cells in the G0 and G1 phase
have a diploid DNA content (2N), whereas cells in G2 or mitosis
have a 4N DNA content. For PI staining, 0.4 million HeLaS3 cells
were seeded, for example, on a 75 cm.sup.2 cell culture flask, and
after 24 h either 1% DMSO was added as control or the substance was
added in various concentrations (in 1% DMSO). The cells were
incubated for 24 h with the substance or with DMSO, before the
cells were washed with 2.times.PBS and detached with trypsin/EDTA.
The cells were centrifuged (1000 rpm, 5 min, 4.degree. C.), and the
cell pellet was washed 2.times. with PBS, before the cells were
resuspended in 0.1 ml of PBS. Then the cells were fixed with 80%
ethanol for 16 hours at 4.degree. C. or alternatively for 2 hours
at -20.degree. C. The fixed cells (10.sup.6 cells) were centrifuged
(1000 rpm, 5 min, 4.degree. C.), washed with PBS and then
centrifuged again. The cell pellet was resuspended in 2 ml of
Triton X-100 in 0.25% PBS, and incubated for 5 min on ice, before 5
ml of PBS were added and the mixture was centrifuged again. The
cell pellet was resuspended in 350 .mu.l of PI stain solution (0.1
mg/ml of Raze A, 10 .mu.g/ml of presidium iodide in 1.times.PBS).
The cells were incubated for 20 min in the dark with the stain
buffer before being transferred into sample measuring vessels for
the FACS scan. The DNA measurement was carried out in a Becton
Dickinson FACS Analyzer, with an argon laser (500 mW, emission 488
nm), and the DNA Cell Quest Program (BD). The logarithmic PI
fluorescence was determined with a band-pass filter (BP 585/42).
The cell populations in the individual phases of the cell cycle
were quantified with the ModFit LT program of Becton Dickinson.
[0248] The compounds of general formula (I) may be used on their
own or combined with other active substances according to the
invention, optionally also in conjunction with other
pharmacologically active substances. Suitable preparations include
for example tablets, capsules, suppositories, solutions,
particularly solutions for injection (s.c., i.v., i.m.) and
infusion, syrups, emulsions or dispersible powders. The amount of
pharmaceutically active compound in each case should be in the
range from 0.1-90 wt. %, preferably 0.5-50 wt. % of the total
composition, i.e. in amounts which are sufficient to achieve the
dosage range given below. The doses specified may, if necessary, be
given several times a day.
[0249] Suitable tablets may be obtained, for example, by mixing the
active substance(s) with known excipients, for example inert
diluents such as calcium carbonate, calcium phosphate or lactose,
disintegrants such as corn starch or alginic acid, binders such as
starch or gelatine, lubricants such as magnesium stearate or talc
and/or agents for delaying release, such as carboxymethyl
cellulose, cellulose acetate phthalate, or polyvinyl acetate. The
tablets may also comprise several layers.
[0250] Coated tablets may be prepared accordingly by coating cores
produced analogously to the tablets with substances normally used
for tablet coatings, for example collidone or shellac, gum arabic,
talc, titanium dioxide or sugar. To achieve delayed release or
prevent incompatibilities the core may also consist of a number of
layers. Similarly the tablet coating may consist of a number of
layers to achieve delayed release, possibly using the excipients
mentioned above for the tablets.
[0251] Syrups or elixirs containing the active substances or
combinations thereof according to the invention may additionally
contain a sweetener such as saccharin, cyclamate, glycerol or sugar
and a flavour enhancer, e.g. a flavouring such as vanillin or
orange extract. They may also contain suspension adjuvants or
thickeners such as sodium carboxymethyl cellulose, wetting agents
such as, for example, condensation products of fatty alcohols with
ethylene oxide, or preservatives such as p-hydroxybenzoates.
[0252] Solutions for injection and infusion are prepared in the
usual way, e.g. with the addition of preservatives such as
p-hydroxybenzoates, or stabilisers such as alkali metal salts of
ethylenediamine tetraacetic acid, optionally using emulsifiers
and/or dispersants, while if water is used as the diluent organic
solvents may optionally be used as solubilisers or auxiliary
solvents, and transferred into injection vials or ampoules or
infusion bottles.
[0253] Capsules containing one or more active substances or
combinations of active substances may for example be prepared by
mixing the active substances with inert carriers such as lactose or
sorbitol and packing them into gelatine capsules.
[0254] Suitable suppositories may be made for example by mixing
with carriers provided for this purpose, such as neutral fats or
polyethyleneglycol or the derivatives thereof.
[0255] Suitable excipients may be, for example, water,
pharmaceutically acceptable organic solvents, such as paraffins
(e.g. petroleum fractions), oils of vegetable origin (e.g.
groundnut or sesame oil), mono- or polyfunctional alcohols (e.g.
ethanol or glycerol), carriers such as e.g. natural mineral powders
(e.g. kaolin, clays, talc, chalk), synthetic mineral powders (e.g.
highly dispersed silica and silicates), sugar (e.g. glucose,
lactose and dextrose), emulsifiers (e.g. lignin, spent sulphite
liquors, methylcellulose, starch and polyvinylpyrrolidone) and
lubricants (e.g. magnesium stearate, talc, stearic acid and sodium
lauryl sulphate).
[0256] The preparations are administered in the usual way,
preferably by oral or transdermal route, particularly preferably by
oral route. When administered orally the tablets may, of course,
contain additives, such as e.g. sodium citrate, calcium carbonate
and dicalcium phosphate together with various additives, such as
starch, preferably potato starch, gelatine and the like, in
addition to the abovementioned carriers. Lubricants such as
magnesium stearate, sodium laurylsulphate and talc may also be used
to form tablets. In the case of aqueous suspensions the active
substances may be combined with various flavour enhancers or
colourings in addition to the abovementioned excipients.
[0257] For parenteral use, solutions of the active substances may
be prepared using suitable liquid carrier materials.
[0258] The dosage for intravenous use is 1-1000 mg per hour,
preferably between 5-500 mg per hour.
[0259] However, it may optionally be necessary to deviate from the
amounts specified, depending on the body weight or method of
administration, the individual response to the medication, the
nature of the formulation used and the time or interval over which
it is administered. Thus, in some cases, it may be sufficient to
use less than the minimum quantity specified above, while in other
cases the upper limit specified will have to be exceeded. When
large amounts are administered it may be advisable to spread them
over the day in a number of single doses.
[0260] The formulation examples that follow illustrate the present
invention without restricting its scope:
Examples of Pharmaceutical Formulations
[0261]
2 A) Tablets per tablet active substance 100 mg lactose 140 mg corn
starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg
500 mg
[0262] The finely ground active substance, lactose and some of the
corn starch are mixed together. The mixture is screened, then
moistened with a solution of polyvinylpyrrolidone in water,
kneaded, wet-granulated and dried. The granules, the remaining corn
starch and the magnesium stearate are screened and mixed together.
The mixture is compressed to produce tablets of suitable shape and
size.
3 B) Tablets per tablet active substance 80 mg lactose 55 mg corn
starch 190 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone
15 mg sodium-carboxymethyl starch 23 mg magnesium stearate 2 mg 400
mg
[0263] The finely ground active substance, some of the corn starch,
lactose, microcrystalline cellulose and polyvinylpyrrolidone are
mixed together, the mixture is screened and worked with the
remaining corn starch and water to form a granulate which is dried
and screened. The sodiumcarboxymethyl starch and the magnesium
stearate are added and mixed in and the mixture is compressed to
form tablets of a suitable size.
4 C) Ampoule solution active substance 50 mg sodium chloride 50 mg
water for inj. 5 ml
[0264] The active substance is dissolved in water at its own pH or
optionally at pH 5.5 to 6.5 and sodium chloride is added to make it
isotonic. The solution obtained is filtered free from pyrogens and
the filtrate is transferred under aseptic conditions into ampoules
which are then sterilised and sealed by fusion. The ampoules
contain 5 mg, 25 mg and 50 mg of active substance.
* * * * *